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CHAPTER 1 - INTRODUCTION 
1.  Introduction 
 Porcine circovirus (PCV) was initially described as a contaminant of the continuous 
porcine kidney cell line PK-15 in 1974 (Tischer et al., 1974). It is a covalently closed single-
stranded DNA virus belonging to the genus Circovirus in the family Circoviridae (Tischer et 
al., 1982). In early studies it was determined that PCV is ubiquitous, but non-pathogenic 
(Tischer et al., 1986). In 1991, a severe wasting disorder was observed in pigs shortly after 
weaning in western Canada (Harding et al., 1997; Clark, 1997), the United States (Allan et 
al., 1998b), and Europe (LeCann et al., 1997; Allan et al., 1998b). Although PCV was 
identified in tissues from affected pigs, it was determined to differ from the original PCV 
genome by 24% to 32% (Meehan et al., 1998; Cheung et al., 2007). This led to classification 
of PCV into two distinct genotypes: the original non-pathogenic strain or PCV type 1 (PCV1) 
and the newly isolated, pathogenic strain or PCV type 2 (PCV2) (Meehan et al., 1998). 
Further genomic alignments revealed that PCV2 could be separated into two distinct groups: 
group 1 comprised of three distinct clusters (1A to 1C), and group 2 comprised of five 
distinct clusters (2A to 2E) (Olvera et al., 2007). Due to multiple designations for these 
groups (de Boisseson C. et al., 2004; Olvera et al., 2007; Timmusk et al., 2008; Grau-Roma 
et al., 2008; Carman et al., 2008), use of lower case letter designations for each group was 
proposed by Segalés et al. (2008) for uniformity, resulting PCV2 group 1 becoming PCV2a 
and PCV2 group 2 becoming PCV2b (Segalés et al., 2008). 
 Since its original identification as the etiological agent of postweaning multisystemic 
wasting syndrome (PMWS) (Ellis et al., 1998; Meehan et al., 1998; Allan et al., 1998a), 
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PCV2 has been associated with multiple disease manifestations, collectively referred to as 
PCV-associated disease (PCVAD) (Opriessnig et al., 2007). Besides PMWS (Clark, 1997; 
Harding et al., 1998), these disease manifestations include respiratory disease (Kim et al., 
2003), enteric disease (Kim et al., 2004), reproductive failure (West et al., 1999), and porcine 
dermatitis and nephropathy syndrome (PDNS) (Choi et al., 2001). All are considered of high 
economic importance due to their contribution to ill-thriftiness, morbidity rates varying 
between 12.5% and 59% (USDA, 2008), and variable mortality rates (López-Soria et al., 
2005; Calsamiglia et al., 2007; Alarcon et al., 2011; Grau-Roma et al., 2012).  
 PCV2 is considered ubiquitous and is prevalent globally (Tischer et al., 1986; Dulac 
et al., 1989; Edwards et al., 1994; Allan et al., 2000; Walker et al., 2000; Zhou et al., 2006; 
Segalés et al., 2008) due to both its resilience to inactivation methods (Allan et al., 1994; 
Welch et al., 2006; O'Dea et al., 2008) and its numerous methods of transmission. These 
include horizontal transmission routes such as colostrum (Shibata et al., 2006), feces (Shibata 
et al., 2003), invertebrate vectors (Blunt et al., 2011), nasal secretions (Shibata et al., 2003), 
oral secretions (Shibata et al., 2003), and seminal fluids (Larochelle et al., 2000). Vertical 
transmission routes include either early crossing of the zona pellucida resulting in oocyte 
infection (Bielanski et al., 2004; Mateusen et al., 2004) or intrauterine fetal infection during 
dam viremia (West et al., 1999; O'Connor et al., 2001; Ladekjær-Mikkelsen et al., 2001; 
Nielsen et al., 2004; Park et al., 2005; Madson et al., 2009b).  
 In response to a large outbreak of PCVAD in late 2005 (Cheung et al., 2007), which 
coincided with a global shift of PCV2a towards PCV2b (Cheung et al., 2007; Gagnon et al., 
2007; Olvera et al., 2007; Segalés et al., 2008), PCV2 vaccines were introduced on the North 
American market in 2006. To date, there are five commercially available vaccines, four of 
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which are licensed for use in the United States by the United States Department of 
Agriculture. These vaccines use three different methods of antigen delivery, all are licensed 
for use in weaning age pigs, and one is additionally licensed for use in breeding dams. The 
first developed vaccine, Circovac® (Merial Inc.), was experimentally launched in 2004 
(Reynaud et al., 2004a, 2004b) and was initially only available in France and Germany under 
special license (Charreyre et al., 2005), but was globally licensed in late 2007 (Burch, 2008). 
Circovac® is based on an inactivated PCV2a, and is unique that it is licensed for both 
weaning age piglets and breeding dams. It is currently licensed for use in the US, but is not 
commercially available. Fostera™ PCV (Pfizer Animal Health Inc.) is a reformulated version 
of Suvaxyn® PCV (Fort Dodge Animal Health Inc.), and was launched in North America in 
2011 after Suvaxyn® PCV was voluntarily removed from the market in May 2010 in 
response to concerns of improper inactivation (Gagnon et al., 2010). Fostera™ PCV is based 
on an inactivated chimeric virus in which the capsid gene of PCV2a is cloned into the non-
pathogenic backbone of PCV1 (Fenaux et al., 2004) which has been demonstrated to be 
attenuated in vivo (Fenaux et al., 2003). Fostera™ PCV is used as a single dose in weaning 
age pigs. The remaining three vaccines are all based on ORF2 protein expressed in a 
baculovirus vector system (Beach et al., 2012). Ingelvac® CircoFLEX™ (Boehringer 
Ingelheim Vetmedica Inc.) is administered as a single dose to weaning age pigs while 
Circumvent® PCV (Merck Inc.) is administered as two doses at weaning and two weeks 
later. Both vaccines are licensed for use and commercially available in the US. Porcilis® 
PCV (MSD Inc.) is administered as a single dose at weaning and is not currently available in 
the US. 

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 Within the PCV2 literature, there have only been two peer-reviewed meta-analyses; 
one on experimental trials with PCV2 (Tomás et al., 2008) and the other on general efficacy 
of PCV2 vaccines (Kristensen et al., 2011). Furthermore, there have also been three meta-
analyses presented at conferences, which focused solely on the performance of Ingelvac® 
CircoFLEX™ (Holck et al., 2010; Diaz et al., 2010; Coll et al., 2010). Thus, our first study, a 
pairwise meta-analysis of the commercially available PCV2 vaccines in the United States, 
was performed using previous literature through a critical review and comparing the efficacy 
of the vaccines compared to no vaccine administration. 
In the US, PCV2 vaccination is currently only licensed for use in pigs at 21 days of 
age or older. However, producers commonly vaccinate piglets against PCV2 during routine 
processing of piglets, including teeth clipping, tail docking, castration, and iron 
administration which occurs within the first few days of life (Marchant-Forde et al., 2009), in 
an attempt to minimize handling and stress. Thus, the main objective of our second study was 
to compare two commercially available vaccines, and their efficacy in 5-day-old and 21-day-
old piglets. 
 Recently, much attention has been given to the role of dam vaccination and vertical 
transmission of PCV2 (Madson et al., 2009a; Madson et al., 2009c; Madson et al., 2011; 
Kurmann et al., 2011). Furthermore, a recent field study across North America demonstrated 
a 44.8% (226/504) prevalence of PCV2 viremia in neonatal piglets with a large portion of the 
piglets appearing normal and healthy (Shen et al., 2010). To further characterize the role of 
dam PCV2 vaccination in newborn piglet viremia, our third study focused on extra-label use 
of a commercial available piglet vaccine in breeding females. Randomly selected dams were 
vaccinated with the PCV2 vaccine prior to insemination or left unvaccinated. At parturition, 

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blood samples were collected from five healthy, randomly-selected piglets from each litter 
and colostrum was collected from the dam to determine if vaccination of the dam reduces the 
presence of PCV2 in the colostrum and the offspring. 
2.  Thesis organization 
 This thesis has been organized using the alternate manuscript format, containing an 
introduction, three separate chapters, and a conclusion. Two of the three chapters are 
scientific manuscripts. References for the introduction and conclusion are cited at the end of 
this document in the "References” section. References for all other chapters are cited at the 
end of each chapter. 
 The first chapter is the introduction to the topic. The second chapter serves as a 
literature review in the form of a pairwise meta-analysis. The third chapter is a scientific 
manuscript on efficacy of two commercially available vaccines in 5-day-old and 21-day-old 
piglets, published in Clinical and Vaccine Immunology (O'Neill et al., 2011). The fourth 
chapter is a scientific manuscript on the effect of dam vaccination on offspring PCV2 
viremia. This manuscript is published in the Veterinary Record (O'Neill et al., 2012). The 
fifth and final chapter is a summary of the conclusions presented within this thesis. 
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CHAPTER 2 – CRITICAL REVIEW AND PAIRWISE META-
ANALYSIS OF THE THREE COMMERCIALLY AVAILABLE PCV2 
VACCINES IN THE UNITED STATES. 
1. Abstract 
Porcine circovirus type 2 (PCV2) vaccines have become one of the most frequently 
administered vaccines to growing pigs worldwide since they became commercially available 
in 2006. They are generally considered to be very effective. While there are multiple studies 
on the efficacy of a singular PCV2 vaccine, there are few studies investigating the overall 
effect PCV2 vaccines on the swine industry.  
Objective: To perform a pairwise meta-analysis of the three commercially available PCV2 
vaccines in the United States. 
Data sources: A literature search for relevant studies using three major databases (PubMed, 
CAB Abstracts, and AGRICOLA) and the proceedings of the American Association of 
Swine Veterinarians Conference, Allen D. Leman Swine Conference, Iowa State University 
Swine Disease Conference for Swine Practitioners, and the International Pig Veterinary 
Society Congress was conducted. Additionally, a search of the United States Department of 
Agriculture (USDA) Center for Veterinary Biologics (CVB) licenses and provisions was 
performed. 
Study selection: Only randomized field studies of the three commercially available, USDA 
licensed PCV2 vaccines administered according to manufacturers’ specifications were 
included. The outcome of interest was the average daily gain (ADG) from wean to finish. 
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Data extraction: Independent extraction of studies by two researchers was performed using 
pre-defined parameters for data, including risk bias analysis. These data were then used in a 
pairwise meta-analysis. 
Data synthesis: Pigs vaccinated with Ingelvac® CircoFLEX™ (13 trials, n=5,417) 
experienced a greater ADG, with a mean difference of 27.84 g/day (95% CI, 20.06 – 35.63) 
over non-vaccinated pigs in the same trials (n=5,078). Pigs vaccinated with Circumvent® 
PCV (6 trials, n=587) also had a greater ADG (mean difference=39.45; 95% CI, 31.27 – 
47.63) than their non-vaccinated counterparts (n=544). Interestingly, pigs vaccinated with 
either Suvaxyn® PCV2 or Fostera™ PCV (2 trials, n=385) had a greater, though not 
significant, ADG (mean difference=44.76; 95% CI, -14.32 – 103.84) when compared to non-
vaccinated pigs (n=375). Furthermore, there was no difference in ADG between studies in 
which the herds were porcine reproductive and respiratory syndrome virus (PRRSV) positive 
or PRRSV negative. 
Conclusions: All products reviewed in this pairwise meta-analysis demonstrated increases in 
ADG, though only Ingelvac® CircoFLEX™ and Circumvent® PCV demonstrated 
significant differences between vaccinated and non-vaccinated animals. Likely, the small 
numbers of studies available for Suvaxyn® PCV2/Fostera™ PCV limited its applicability to 
the pairwise meta-analysis. 
2. Introduction 
 Vaccination against porcine circovirus (PCV) type 2 (PCV2) is a common method to 
protect growing pigs against the clinical disease manifestations associated with PCV2, 
commonly referred to as porcine circovirus associated disease (PCVAD) (Opriessnig et al., 
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2007b). Vaccines against PCV2 were developed, licensed, and initially distributed in the 
United States in 2006 in response to a severe outbreak of PCVAD in North America in 2005 
and 2006 (Cheung et al., 2007). There are indications from the field that PCV2 vaccines are 
efficacious at preventing disease and increasing production parameters (Kixmöller et al., 
2008; Fachinger et al., 2008; Gillespie et al., 2009).  
To date, there are three commercial vaccines licensed and available for use in pigs 
three weeks of age and older in the United States. Fostera™ PCV (Pfizer Animal Health, 
New York, NY), a reformulated version of Suvaxyn® PCV (Fort Dodge Animal Health, Fort 
Dodge, IA), uses an inactivated chimeric PCV1-2 virus, in which the capsid gene of PCV2a 
is cloned into the non-pathogenic PCV type 1 (PCV1) backbone. This vaccine is 
administered in a single dose. Ingelvac® CircoFLEX™ (Boehringer Ingelheim Vetmedica, 
St. Joseph, MO) and Circumvent® PCV (Merck Animal Health, Omaha, NE) both are based 
on the PCV2a capsid gene expressed in a baculovirus vector. CircoFLEX® is delivered as a 
single dose, while Circumvent® PCV is administered in two doses three weeks apart from 
each other. Currently, available product efficacy data are limited to studies utilizing an 
individual product, and comparison data of efficacy among vaccines are limited.  
 We are aware of only one peer-reviewed meta-analysis summarizing the effect of 
commercially available PCV2 vaccines (Kristensen et al., 2011). The current review updates 
that meta-analysis and makes greater use of data derived estimates of variation of the 
outcome ADG. The prior meta-analysis used the inverse of the study size to describe within-
study variation of ADG and to calculate the summary effect measure. Such an approach is 
not ideal as it assumes that variation in the study population is a direction function of sample 
size whereas in reality, variation in the ADG in pigs may be a function of many factors. In 
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this review we incorporated variation estimates from each study where possible. Narrative 
reviews serve a great purpose in assembling and summarizing current knowledge, but 
systematic reviews allow for in-depth inspection of collective data using a concentrated study 
question, reproducible search and extraction methods, and bias analysis. The data obtained 
through the systematic review process can then be easily adapted for use in an overall meta-
analysis.  
The objective of this study was to summarize an estimate of efficacy and impact of 
commercially available PCV2 vaccines when used in intensively raised swine. In this review 
we conducted a pairwise meta-analysis of the three commercially available PCV2 vaccines in 
the US, relative to no vaccine.   
3. Materials and Methods 
I. Protocol and registration. 
A review protocol was developed using Review Manager 5.1 (RevMan 5.1, 
Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). The search 
strategy was modified after the protocol was established based on suggestions from experts 
(D. Holtkamp, P. Halbur) outside the review team (K. O’Neill, A. O’Connor, T. Opriessnig). 
Also, due to anticipated difficulties with the data analysis, the protocol only proposed mixed 
treatment comparison (MTC) meta-analysis and did not specify the exact method of data 
analysis. This paper describes a pairwise meta-analysis of each vaccine compared to a non-
active control arm as an intermediary step in the review, prior to conducting the MTC. The 
rationale for conducting a pairwise meta-analysis prior to an MTC is to enable verification of 
the data and establish exceptions for associations prior to conducting an MTC. 
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II. Eligibility criteria 
The PICOS-based question (P=population; I=intervention; C=comparator; 
O=outcome; S=study design) for the critical review (Sargeant et al., 2006) was developed in 
consultation with a veterinary epidemiologist (A. O’Connor) and a veterinary pathologist (T. 
Opriessnig). The final question agreed upon was “What is the effect of each of the three 
commercially available PCV2 vaccines compared to no vaccines on average daily gain 
between weaning and marketing in commercial pigs naturally exposed to PCV2 where the 
porcine reproductive and respiratory syndrome virus (PRRSV) status is known?” Within the 
PICOS format of the question development, the population of interest was defined as 
intensively raised pigs in a modern, commercial setting. The intervention was defined as any 
United States Department of Agriculture (USDA) licensed, commercial PCV2 vaccine 
available in the US administered as prescribed by the manufacturer, though its use was not 
geographically limited. The comparator of interest was defined as a non-active arm such as 
no vaccine, saline, etc. The outcome was defined as average daily gain (ADG) (g/day) from 
wean to finish. The study design of interest was randomized trials with naturally occurring 
PCV2 exposure and disease, i.e. experimental studies were excluded. 
III. Information sources 
Studies relevant to the review were chronologically self-limited as vaccines have only 
been commercially available since 2006. Therefore the search data for relevant studies were 
limited to a beginning date of January 1st, 2006, and to publication in English, Spanish, and 
Portuguese due to scientific staff fluency and lack of reliable translation software.  
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A subject librarian specializing in veterinary medicine (A. Dinkelman) was consulted 
for the development of a Boolean search string for an electronic database search of PubMed 
(http://www.ncbi.nlm.nih.org/pubmed/), AGRICOLA (EBSCOhost® Research Database, 
EBSCO® Publishing, Ipswich, MA), and CAB Abstracts (Web of Knowledge™, Thomson 
Reuters, New York, NY). An additional limit was to adjust the search engine for articles 
pertaining to animals. Searches were performed on April 27th, 2012, May 1st, 2012, and May 
8th, 2012. On May 17th, 2012 a non-Boolean search of the USDA Center for Veterinary 
Biologics (CVB) was performed to both confirm the current product licensure for the United 
States (USDA, 2012) and to potentially find the required studies for licensure (USDA, 2011; 
USDA, 2012).  
A search of the Swine Information Library (http://www.aasv.org/library/swineinfo/) 
through the proceedings of the International Pig Veterinary Society (IPVS) Congress, the 
American Association of Swine Veterinarians (AASV) conference, the Allen D. Leman 
Swine Conference, and the Iowa State University (ISU) Swine Disease Conference for Swine 
Practitioners from 2006 to 2012 was also performed between August 28th, 2012 and August 
30th, 2012. 
IV. Example search 
Individual parameters directly applicable to the PICOS-formulated question were 
chosen with the aid of the subject librarian and were entered into the following search string 
with Boolean operators: “population of interest” AND “outcome” AND “intervention” 
(Table 1). The PubMed search string was as follows: (Barrow OR Barrows OR Boar OR 
Boars OR Feeder OR Finishing OR Gilt OR Gilts OR Hog OR Hogs OR Pig OR Piglet OR 
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Piglets OR Pigs OR Porcine OR Shoats OR Sow OR Sows OR Swine) AND (“Acute 
Pulmonary Edema” OR “Acute Pulmonary Oedema” OR Circoviridae OR Circovirus OR 
PCV OR PCV2 OR PCV-2 OR PCVAD OR PCVD OR PMWS OR “Porcine circovirus” OR 
“Porcine circovirus 2” OR “Porcine circovirus associated disease” OR “Porcine circovirus 
disease” OR “Porcine circovirus type 2” OR “Porcine circovirus-2” OR “Porcine 
respiratory disease complex” OR “Postweaning multisystemic wasting disorder” OR 
“Porcine Postweaning Multisystemic Wasting Syndrome [MeSH]” OR PRDC) AND 
(Immunisation OR Immunise OR Immunised OR Immunity OR Immunization OR Immunize 
OR Immunized OR Immunoprophylaxis OR Intervention [tiab] OR Interventions [tiab] OR 
Vaccinate OR Vaccinated OR Vaccination OR Vaccinations OR Vaccine OR Vaccines). The 
only restrictions imposed were chronological limitation of the publication dates spanning 
2006/01/01 to 2012/05/01 and setting the species from Humans to Other Animals. 
All citations retrieved were imported into a reference managing database (Reference 
Manager® ver. 11, Thomson Reuters) in which duplicates were eliminated, either through 
software detection or manual review.  
V. Study selection process 
In this review, “study” was considered a clinical trial which fulfilled the eligibility 
criteria and there could be multiple “studies” per article. Once records were retrieved they 
were evaluated for eligibility based on the following screening questions: 1) Does the study 
describe an assessment of one of the three listed commercially available PCV2 vaccines 
within a field trial with a natural exposure? 2) Does the study report both the vaccine and is 
its administration in accordance with the manufacturers’ specifications? 3) Does the study 


 
report ADG (wean to finish)? 4) Is the PRRSV status of the herd included? These questions 
were evaluated using five abstracts by three individuals (A. O’Connor, T. Opriessnig, K. 
O’Neill) and modified to ensure they selected the correct studies. After this step screening of 
the remaining citations was conducted by only one person (K. O’Neill). 
The screening process was conservative, i.e., a record was considered relevant until 
found not to be. Initial screening of a study for relevance was performed at the title level, 
where ambiguous titles containing any combination of terms from the Boolean search string 
were conservatively considered relevant, unless they explicitly described a trial that utilized a 
vaccine other than the three licensed for commercial use in the US. Further review of each 
study, first through the abstract, then, if not clearly defined there, the full text, was based on 
the above questions. 
Any negative response to the first three of these questions deemed the study 
ineligible. Authors of otherwise qualifying studies were contacted via e-mail to identify the 
PRRSV status of the herd within the study. Failure to identify the PRRSV status of the herd, 
through either extraction or electronic contact meant the study was outside of the scope of the 
review. The rationale of this eligibility criteria was that a previous meta-analysis of general 
PCV2 vaccine efficacy (Kristensen et al., 2011) regarded PRRSV status as a potential source 
of clinical variation and excluded studies if PRRSV was not identified as being absent or 
present in the herd, although PRRSV status classification was not addressed (Kristensen et 
al., 2011). Furthermore, previously reported high incidences of disease manifestations 
associated with concurrent PCV2 and PRRSV (Pallarés et al., 2002; Wellenberg et al., 2004; 
Grau-Roma et al., 2007) indicate a substantial role of PRRSV in the pathogenicity of PCV2.  
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VI. Data collection process 
Once a study was considered relevant, data available in English, Spanish, and 
Portuguese were extracted by two Master level students (K. O’Neill, P. Gerber), specialized 
in PCV2 research, working independently. The forms for data extraction were not pretested 
or piloted. Conflicts between the two researchers were identified and resolved by one 
reviewer (K. O’Neill). After data extraction was completed, five randomly selected relevant 
papers were sent to an independent reviewer, unconnected to the project (R. Dzika) to verify 
the extraction of outcome data.  The independent reviewer did not assess demographic or 
bias data extraction.  The results of that exercise identified disagreements for three of the five 
studies, which were resolved through discussion. The primary reviewer (K. O’Neill) then 
modified the output presentation for all extracted data after that discussion to reduce errors. 
4. Data items collected  
I. Outcome data 
For the primary outcome, ADG in g/day from weaning (approximately three weeks of 
age) to finish (approximately 23 weeks of age) data were required for each arm of each trial.  
Outcome data extracted included ADG (wean to finish) for each arm, the sample size for 
each group, measures of variation i.e. SD, SEM or p-values when reported.  
 The units for the primary summary measure of ADG were converted to grams per day 
for all studies. In some instances studies did not report ADG for the required period from 
weaning to finish. In these cases, although it seemed likely that the study would have 
generated the desired information, the study was not incorporated into the meta-analysis. On 
several occasions, the data could be extracted with manipulation and was done by combining 
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either multiple groups (i.e. the original study report listed the data stratified by sex) or 
production stage time measurements (i.e. ADG with measures of variation were reported 
separate for nursery, grow-finish, and finish stages for a single group).  
Some studies reported weight measurements and measures of variation for all 
necessary time points, but the authors did not calculate or clearly report ADG.  In these 
instances, the ADG was calculated using the equation 
( ), and then the reported measures of variation 
were conservatively calculated using ( ). 
To calculate overall ADG from an individual herd in which the data was reported in 
separate production stages, the following equation was incorporated: 
 . 
To account for inconsistent measure of variation for the ADG reporting, the standard 
deviation (SD) of each treatment group mean was derived when not reported. Meta-analysis 
requires ADG and SD for each study group, and if this information was not reported we used 
wherever possible the RevMan 5.1 statistical calculator (RevMan) to calculate the SD for 
each treatment group mean. When reporting was incomplete, such as authors reported a 
probability value (p-value) only, back-calculation was conducted to determine the measures 
of variation. However, if the number of animals enrolled and the ADG were not reported it 
was not possible to extrapolate the needed numbers, and although relevant to the review the 
studies’ results could not be included in the meta-analysis.  
If a p-value was reported, the p-value, mean difference, and population were used to 
derive a T-statistic (RevMan). The T-statistic was then used in the equation   = 
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SEMean Difference. The derived SEMean Difference was entered in the RevMan 5.1 statistical 
calculator (RevMan) with the p-value, mean difference, and population data points to obtain 
the SD for each mean. Furthermore, the p-value was conservatively used in these instances, 
i.e. for studies that reported p<0.05 we used p=0.05 in our calculations.  
When ADG was reported within a single herd but reported in various production 
stages, the measures of variation generally had to be combined similarly. This resulted in a 
conservative estimation of the overall SD using the following equation: 
 . 
II. Intervention, and clinical and methodological sources of heterogeneity   
Information about the interventions was also extracted i.e. the PCV2 vaccine used, 
timing, and control treatments. Information collected from the studies included the sources of 
clinical and methodological heterogeneity and the outcome of interest and vaccination age. 
Extracted information about potential sources of clinical heterogeneity included variables 
such as location (country) and PRRSV status (negative or positive). Extracted 
methodological sources of variation included the unit of treatment allocation (pig/piglet/sow, 
pen, barn, etc.), method of allocation to treatment group i.e. did the authors report 
randomization (yes or no), and whether blinding of the outcome assessor to the treatment 
group status was reported (yes or no). Information about allocation concealment and methods 
of sequence generation were not extracted.   
Studies which used pen and barn level allocations were reviewed to determine if 
treatment group integrity was maintained, which could bias the estimates of ADG (Van 
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Vleck et al., 2005). To account for this, pen effects were entered in the model as random 
effects (Chen et al., 2008). 
To avoid over-estimation of ADG, only studies which accounted for mortality in 
ADG calculation (Booker et al., 2007) were determined eligible. When ADG needed to be 
calculated, mortality was accounted for, and only pigs that survived until the finishing phase 
were included.  
During the data collection process, investigators were contacted via e-mail for 
clarification of certain data, such as PRRSV status of the herd, measures of variation, and 
methods of allocation to group such as blocking and randomization.   
There is a clearly documented difference of PCV2-associated microscopic lesions 
(lymphoid depletion and granulomatous inflammation) in purebred Landrace pigs compared 
to Pietrain, Large White, and Duroc pigs (Opriessnig et al., 2006a; Opriessnig et al., 2009d), 
and breed genetics have accounted for differences in susceptibility to disease from other viral 
infections such as PRRSV (Halbur et al., 1998) and pseudorabies virus (Reiner et al., 2002). 
While this could introduce bias to this study, crossbreeding is typically utilized by pork 
producers to optimize production (Bennett et al., 1983). If the herd breed was disclosed, it 
was documented, but the assumption to treat all breeds equally in this study was made due to 
the animals in question housed in intensive swine production units which utilize 
crossbreeding (Kuhlers et al., 1994). 
III. Risk of bias in individual studies 
The methods of randomization and blinding as part of the Data items in the Data 
collection process were evaluated for a potential bias using the Cochrane risk bias 
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assessment tool (Higgins et al., 2011). All studies were assessed for risk of bias due to 
allocation of interventions (Selection bias), blinding of personnel (Performance bias), and 
blinding of outcome assessment (Detection bias). This was performed at the individual study 
level as opposed to the outcome level. This risk of bias was assessed by two Master level 
students (K. O’Neill, P. Gerber), with familiarity in executing challenge studies in veterinary 
medicine, but no familiarity with conducting field trials or formal training in biases of 
clinical trials in veterinary science. Disagreements in bias assessment were discussed and 
resolved by the students during the compilation of the final data set. 
IV. Summary measures 
 The summary measure of the outcome for each trial was the mean difference between 
treatments (ADG vaccinated arm – ADG unvaccinated arm). As our hypothesis was that the 
vaccines would increase ADG, we expected that the mean difference would be positive i.e., 
greater than zero. 
V. Synthesis of results 
 The approach to synthesis was to conduct three pairwise meta-analyses. The summary 
effect measure for this outcome was the mean difference in ADG. A fixed effects and a 
random effects model were calculated using the Meta package in R version 2.15.1 (R 
Development Core Team). The hypothesis was that the overall difference was equal to the 
null value (mean difference = 0). A subgroup analysis based on the PRRSV status was also 
conducted.  The aim of the subgroup analysis was to assess if PRRSV status was a source of 
heterogeneity.  Overall and within subgroup heterogeneity was assessed using the chi-square 
test. The null hypothesis was that heterogeneity was not present. All tests of heterogeneity 
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were reported at the subgroup and group level. First, subgroup heterogeneity was assessed. If 
the p-value for heterogeneity between the subgroup effects was significant (P<0.01), it was 
inferred that the subgroups were different. If the p-value for subgroup heterogeneity was 
greater than 0.01, the subgroup was not a source of heterogeneity. The subgroups were then 
collapsed, and heterogeneity was assessed across the entire population. We also reported the 
I2 which describes the percentage of variation across studies due to heterogeneity rather than 
chance. I² is an intuitive and simple expression of the inconsistency of studies’ results. The 
data was also used to create a forest plots for each pairwise comparison. We did not assess 
publication bias, the impact of group versus individual level allocation, or other 
methodological sources of bias as predictors of the outcomes.  
VI. Risk of bias across studies 
 The Cochrane risk bias assessment tool (Higgins et al., 2011) was further used for 
evaluation of a potential bias within the cumulative results. All studies were assessed for risk 
of bias due to incomplete outcome data (Attrition bias) and selective reporting (Reporting 
bias). The Other bias portion of the assessment tool was utilized to identify if any authors 
associated with the study were employed by the manufacturer of the vaccine utilized in the 
trial. 
 The reporting source for all the trials was recorded and tabulated as to whether or not 
it was a refereed source, or if it was a conference proceeding. 
5. Results 
I. Study selection 

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 The database search yielded 985 articles overall, of which 161 were further examined 
for inclusion, based on the assessment of the title and abstract. Of these 161 articles, there 
were initially 41 duplicates. Additionally, articles in Czech (two articles), German (three 
articles), Hungarian, (one article), and Polish (one article) were excluded from consideration 
for the review. Within the initial 120 identified articles for inclusion through the database 
search, the publication types were refereed publications (n=69), non-refereed publications 
(n=39), and conference publications (n=12). 
The search for supplemental information from vaccine manufacturers through the 
CVB resulted in three technical bulletins from Boehringer Ingelheim Animal Health Inc. 
(Sanford et al., 2007a; Sanford et al., 2007b; Sanford et al., 2008), one study from Pfizer 
Animal Health Inc. (Neuberger, 2011), and a veterinary product listing in the 12th 
Compendium of Veterinary Products (North American Compendiums Inc., 2010) for Merck 
Animal Health Inc. The technical bulletins from Boehringer Ingelheim Animal Health Inc. 
were excluded as they were duplicates of studies already identified through the database 
search. The study from Pfizer Animal Health Inc. was excluded as it did not describe a 
natural PCV2 exposure. The product listing for Merck Animal Health Inc. was a general 
statement of facts on the Circumvent® PCV product and was therefore excluded.  
Screening of the titles of conference proceedings provided through AASV, the Allen 
D. Leman Swine Conference, IPVS, and the ISU Swine Disease Conference for Swine 
Practitioners proceedings yielded 174 articles of which 27 were duplicates of conference 
presentations or articles already included as part of the database search. The majority of 
relevant conference proceedings came from the IPVS congresses (92 studies), which 
outnumbered the combined amount of proceedings from the AASV conferences (43 studies), 
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the Allen D. Leman Swine Conferences (36 studies), and the ISU Swine Disease 
Conferences (3 studies). The majority of relevant conference proceedings, regardless of 
conference, were presented in 2010 (63 studies). 
The combined total article count from all searches was 270 articles after initially 
discovered duplicates were eliminated (Fig. 1). The 233 articles which were excluded were 
further divided based on the selection criteria in the title, abstract, or text which rendered 
them not relevant to this study and which is demonstrated in Fig. 2. 
II. Study characteristics 
The results obtained for each vaccine are summarized in forest plots in Figs. 3, 4, and 
5. Overall, there was a positive mean difference, regardless of vaccine product, 
demonstrating an increase in ADG with vaccination, although these mean differences were 
likely affected by the variance in sample sizes which was exacerbated by the different units 
of allocation. Additionally, one study (Nerem 2011) had an overly large variance (SD = 
±430.732 g/day). This study only reported a Fisher’s exact test probability (p=0.04), and the 
results were back-calculated identically to other eligible studies which only reported p-values 
(see Outcome data).  
III. Risk of bias within studies 
Assessment of the risk of bias was performed for each study (Fig. 6). The two sources 
of bias which were most prevalent were the potential for Selection bias and Other bias, with 
approximately 50% of the included studies expressing each. The lowest risk of bias was 
observed with Attrition bias, with incomplete outcome data reporting only being encountered 
in one study. 
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IV. Synthesis of results 
The results of the pairwise comparisons for Ingelvac® CircoFLEX, Circumvent® 
PCV, and Suvaxyn® PCV2/Fostera™ are summarized in Figs. 3, 4, and 5, respectively. 
Of the 21 included studies, 13 were studies using the Ingelvac® CircoFLEX™ 
product. Overall, within the preferred random effects model, although the fixed effects model 
was reported as well, there was a mean difference of 27.84 g/day (95% CI, 20.06 – 35.63) 
between vaccinated (n=5,417) and unvaccinated (n=5,078) pigs (Fig. 3) and there was strong 
evidence of heterogeneity (I2 = 81.6%, p<0.0001). Furthermore, out of these 13 studies, eight 
involved PRRSV negative herds and the remaining five were conducted in PRRSV positive 
herds. The studies with a negative PRRSV status had a mean difference of 29.09 g/day (95% 
CI, 16.41 – 41.78) between vaccinated (n=3,235) and unvaccinated (n=2,959) pigs, while the 
studies with a positive PRRSV status had a mean difference of 25.84 g/day (95% CI, 18.26 – 
33.43) between vaccinated (n=2,182) and unvaccinated (n=2,119) pigs. There was no 
difference between PRRSV positive and negative sub-groups (p=0.66), demonstrating little 
evidence of the PRRSV status influencing clinical heterogeneity, although when grouped by 
PRRSV status, the heterogeneity remained at the same level within the PRRSV negative 
trials (I 2 = 87.3%, p<0.0001) but decreased in the PRRSV positive trials (I2 = 47.8%, p = 
0.1048). 
Of the remaining eight studies, six were studies using the Circumvent® PCV product. 
Due to lack of heterogeneity (I2 = 0%, p=0.5884) within these six studies, the fixed and 
random effects models were almost identical. Overall, there was a mean difference of 39.45 
g/day (95% CI, 31.27 – 47.63) between vaccinated (n=587) and unvaccinated (n=544) pigs 
(Fig. 4). When sub-grouped by PRRSV status, there were two PRRSV negative studies with 
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a mean difference of 45.22 g/day (95% CI, 29.08 – 61.36) between vaccinated (n=419) and 
unvaccinated (n=415) pigs, and there were four PRRSV positive studies with a mean 
difference of 37.43 g/day (95% CI, 27.93 – 46.93) between vaccinated (n=168) and 
unvaccinated (n=129) pigs. Furthermore, there was no difference between sub-groups 
(p=0.41), suggesting strong evidence of no clinical heterogeneity. 
The final two studies used Suvaxyn® PCV2/Fostera™ PCV. Within the random 
effects model, there was a mean difference of 44.76 g/day (95% CI, -14.32 – 103.84) 
between vaccinated (n=385) and unvaccinated (n=375) pigs (Fig. 5). Furthermore, both 
studies were of PRRSV positive pigs and displayed strong evidence of heterogeneity (I2 = 
90.5%, p=0.0011). 
When tested for the overall effect, use of the Ingelvac® CircoFLEX™ and 
Circumvent® PCV vaccines resulted in significantly greater (p < 0.0001) daily weigh gains 
than their non-vaccinated counterparts (Fig. 3, 4). However, the average daily gain in pigs 
vaccinated with Suvaxyn® PCV2/Fostera™ PCV was not different (p = 0.13) compared to 
pigs with no vaccination (Fig. 5) in our random effects model.  
6. Discussion 
I. Summary of evidence 
 The objective of this meta-analysis was to utilize published data on the three 
commercially licensed PCV2 vaccines that are currently available in the US, and create a 
comparison of vaccinated and non-vaccinated groups for each product with regards to ADG. 
While there are previous meta-analyses available, they focused on overall vaccine efficacy 
(Kristensen et al., 2011), the performance of Ingelvac® CircoFLEX™ when compared to 
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non-vaccinated animals (Holck et al., 2010; Coll et al., 2010), or the comparative efficacy of 
Ingelvac® CircoFLEX™ against Circumvent® PCV (Diaz et al., 2010). This is, to the 
authors’ knowledge, the first pairwise meta-analysis of all three of the commercially 
available PCV2 vaccines in the US relative to no vaccination.  
 Overall, two of the vaccines were demonstrated to contribute to significant increases 
in ADG. The Circumvent® PCV trials (n=6) demonstrated the most consistent and highest 
ADG increases (39.45 g/day) with the least heterogeneity (I2 = 0%) regardless of the herd 
PRRSV status, followed by the Ingelvac® CircoFLEX™ trials (27.84 g/day) for which we 
assessed data obtained from more individual studies (n=13) compared to the other two 
vaccines, but which also had a greater variation.  
II. Limitations 
  The use of a random effects model was determined the most appropriate approach 
based on the assumption that statistical heterogeneity does not hold true (Higgins et al., 
2011); however, this impacted the analysis of the Suvaxyn® PCV2/Fostera™ PCV trials. A 
higher weight was attributed to the smaller of the two qualified studies which potentially 
introduced a bias (Higgins et al., 2011). Furthermore, the estimate of the distribution was 
poor due to low numbers of the qualifying studies (Higgins et al., 2011), resulting in no 
detectable differences between treatment groups (vaccination; no vaccination) and a greatly 
exaggerated heterogeneity.  
 The use of conference proceedings in a systematic review can improve the pool of 
data for synthesis and minimize a potential bias from language limitations and associated 
exclusion of relevant studies (Sargeant et al., 2006), but can also complicate data synthesis. A 
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major limitation encountered from the addition of conference proceedings was the extremely 
variable methods of data presentation, resulting in conservative estimates of variance based 
on back calculation (Higgins et al., 2011) and a potential overall narrowing of the confidence 
interval due to inconsistent reporting of sample enrollment compared to mortalities as 
previously described (Booker et al., 2007).  
Another concern with the inclusion of conference proceedings was the potential bias 
inclusion. Of the 21 studies included in this meta-analysis, 10 were conference proceedings. 
Fifty percent (5/10) of these conference proceedings were deemed high risk for the Other 
bias during the risk of bias assessment due to authors being employed by the manufacturers 
of the vaccines, and could also not be associated with complementary refereed sources. Both 
of these factors can greatly impact the bias of the study, which is supported by a recent study 
suggesting a higher likelihood to report significant results through conference proceedings 
(Snedeker et al., 2010). 
 Within the Ingelvac® CircoFLEX™ trial portion of the Data synthesis, there were 
two studies which were determined to be outliers from the average mean difference (Maass 
2010a and Ehlorsson 2010). These two outliers were small in size, contributing only 3.3% 
and 5.5% (Maass 2010a and Ehlorsson 2010, respectively) in the weighted random effects 
model. Interestingly, both of these studies were from PRRSV negative herds, and were 
isolated during the sub-group analysis, resulting in a lowering of the heterogeneity score for 
the PRRSV positive sub-group, although there was no significant difference between sub-
groups. While these studies were likely contributing to the observed heterogeneity in this set 
of trials due to either within-study bias or increase of the study weight in the random effects 
model (Poole et al., 1999; Kjaergard et al., 2001; Higgins et al., 2011), it was decided to 
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leave these studies within the data set without sensitivity analysis. This was mainly done due 
to the varying sizes of the other studies (Higgins et al., 2011) and to maintain transparency 
within the reporting of this review (Liberati et al., 2009).  
 While there is a demonstrated difference in ADG between vaccination and no 
vaccination for two of the three products in this study, these data do not demonstrate 
comparative efficacy between these products. The pairwise analysis used does not compile a 
set of internally consistent estimates between the three models, nor does it maintain the 
randomization used in each study (Glenny et al., 2005; Dias et al., 2011). For comparative 
efficacy, a network meta-analysis (Dias et al., 2011) would be required.   
III. Conclusions 
 All products reviewed in this pairwise meta-analysis demonstrated increases in ADG, 
though only Ingelvac® CircoFLEX™ and Circumvent® PCV demonstrated significant 
differences between vaccinated and non-vaccinated pigs. It is likely the small number of 
studies available for Suvaxyn® PCV2/Fostera™ PCV limited its applicability to the pairwise 
meta-analysis. 
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Table 1. The PICOS-derived search parameters and input for the Boolean search string 
“Population of interest” AND “Outcome” AND “Intervention”. All search terms were 
established with the aid of a research librarian to account for lemmatization, regional spelling 
differences, and each database’s thesaurus. 
Population of Interest Outcome Intervention 
Barrow Acute Pulmonary Edema Immunisation 
Barrows APE Immunise 
Boar Circoviridae Immunised 
Boars Circovirus Immunity 
Feeder PCV Immunization 
Finishing PCV2 Immunize 
Gilt PCV-2 Immunized 
Gilts PCVAD Immunoprophylaxis 
Hog PCVD Intervention 
Hogs PMWS Interventions 
Pig Porcine circovirus Vaccinate 
Piglet Porcine circovirus 2 Vaccinated 
Piglets Porcine circovirus associated disease Vaccination 
Pigs Porcine circovirus disease Vaccinations 
Porcine Porcine circovirus type 2 Vaccine 
Shoats Porcine circovirus-2 Vaccines 
Sow Porcine respiratory disease complex  
Sows Postweaning multisystemic wasting disorder  
Swine PRDC  
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Table 2. Summary of the resulting studies from the systematic review included in the Data 
synthesis. PRRSV status was determined from evidence in the studies or through contact with 
the investigators.  
Author, Year Study ID Intervention PRRSV Status 
Unit of 
Treatment 
Allocation 
Study Size (n) 
(Criado, 2012) Criado 2012 Ingelvac® CircoFLEX™ Negative Pig 457 
(Dunlop et al., 
2012) Dunlop 2012 
Ingelvac® 
CircoFLEX™ Negative Pig 2,322 
(Ehlorsson et al., 
2010b) 
Ehlorsson 
2012 
Ingelvac® 
CircoFLEX™ Negative Pig 294 
(Maass et al., 2009) Maass 2010a Ingelvac® CircoFLEX™ Negative Barn 24 
(Maass et al., 2009) Maass 2010b Ingelvac® CircoFLEX™ Negative Pig 1,125 
(Nerem, 2011) Nerem 2011 Ingelvac® CircoFLEX™ Positive Pig 779 
(Richthofen et al., 
2009) 
Richthofen 
2009 
Ingelvac® 
CircoFLEX™ Negative Pig 1,252 
(Weibel et al., 
2010) Weibel 2010 
Ingelvac® 
CircoFLEX™ Negative Pig 672 
(Young et al., 
2011b) Young 2011 
Ingelvac® 
CircoFLEX™ Negative Pen 48 
(Arnold et al., 
2008) Arnold 2008 
Ingelvac® 
CircoFLEX™ Positive Barn 82 
(Fachinger et al., 
2008) 
Fachinger 
2008 
Ingelvac® 
CircoFLEX™ Positive Pig 1,408 
(Kixmöller et al., 
2008) 
Kixmöller 
2008 
Ingelvac® 
CircoFLEX™ Positive Pig 1,434 
(Siebel, 2010) Seibel 2008 Ingelvac® CircoFLEX™ Positive Pig 598 
(Horlen et al., 
2008) Horlen 2008 
Circumvent® 
PCV Negative Pig 417 
(Potter et al., 2012) Potter 2012 Circumvent® PCV Negative Pig 417 
(Jacela et al., 2011) Jacela 2011a Circumvent® PCV Positive Pen 48 
(Jacela et al., 2011) Jacela 2011b Circumvent® PCV Positive Pen 46 
(Shelton et al., 
2009a) Shelton 2009 
Circumvent® 
PCV Positive Pen 46 
(Venegas-Vargas et 
al., 2011) 
Venegas-
Vargas 2011 
Circumvent® 
PCV Positive Pig 157 
(Segalés et al., 
2009) Segalés 2009 
Suvaxyn® 
PCV2 Positive Pig 640 
(Seo et al., 2012) Seo 2012 Fostera™ PCV Positive Pig 120 
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Fig. 1. Flow chart diagramming the 
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Study selection process. 
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Fig. 2.  List of all articles excluded with reasons for exclusion.  
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2010d; Fablet et al., 2011;  Anonymous 2011; Papatsiros, 2011; Madson et al., 2011; Trible et al., 2011; Cino-Ozuna et al., 
2011; Kristensen et al., 2011; Gerber et al., 2011; Puvanendiran et al., 2011; Lehe et al., 2011; Opriessnig et al., 2011a; 
Opriessnig et al., 2011b; Opriessnig et al., 2011c; Rodriguez-Gomez et al., 2012; Oh et al., 2012; Shen et al., 2012; Beach 
et al., 2012; Tshering et al., 2012; Trible et al., 2012a; Trible et al., 2012b) 
(Ellis et al., 2006; Charreyre et al., 2006; Jacela et al., 2007; Erlandson et al., 2007; Nerem, 2007; Paulsson et al., 2008; Hii 
et al., 2008; Janice et al., 2008; Waddilove, 2008; Beek, 2008a; Joisel et al., 2008a; Fort et al., 2008a; Joisel et al., 2008b; 
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Kwang, 2010; del Campo et al., 2010; Eggen et al., 2010b; Menjon et al., 2011; Fraile et al., 2011; Liber et al., 2011; 
Togashi et al., 2011; Kurmann et al., 2011; Pejsak et al., 2011; Lyoo et al., 2011; Murray, 2011; Blood et al., 2011; Wilson 
et al., 2011; Pejsak et al., 2012; Fraile et al., 2012; Dan et al., 2012; Lopez et al., 2012; Wang et al., 2012; Dmitrik et al., 
2012; Payne et al., 2012)
(Connor et al., 2007; Kolb et al., 2007; Diaz et al., 2007; Desrosiers et al., 2007a; de Grau et al., 2007a; de Grau et al., 
2007b; Desrosiers et al., 2007b; Kane et al., 2008; Desrosiers, 2008; Young et al., 2008; Petersen et al., 2008; Gonzalez, 
2008; King et al., 2008; Paphavasit et al., 2008; Urniza et al., 2008; Mette et al., 2008; Neumann et al., 2008; Eichmeyer et 
al., 2008; Lyoo et al., 2008; Zivlavsky et al., 2008; Segalés et al., 2008; Haas et al., 2008; Liesner et al., 2008; Edler et al., 
2008; Bretey et al., 2008; Orveillon et al., 2008; Ramírez et al., 2008; Burch, 2008a; Thacker et al., 2008a; Ritzmann et al., 
2008a; Cline et al., 2008a; Burch, 2008b; Fort et al., 2008b; Thacker et al., 2008b; Ritzmann et al., 2008b; Paphavasit et 
al., 2009; Desrosiers et al., 2009; Neumann et al., 2009; Kane et al., 2009; Connor et al., 2009; Eichmeyer et al., 2009; 
Duflo et al., 2009; Verbeck et al., 2009; Mellencamp et al., 2009; Hesse et al., 2009; Baysinger et al., 2009; Holck et al., 
2009; Diaz, 2009; Maass et al., 2009; Bretey et al., 2009; Kelly et al., 2009; Suprenant et al., 2009; Shelton et al., 2009b; 
Rossi et al., 2010; Desrosiers, 2010; Burch, 2010; Takahagi et al., 2010; Connor et al., 2010; Lyoo et al., 2010; Almond et 
al., 2010; Yong et al., 2010; Channarong et al., 2010; Venegas-Vargas et al., 2010; Pittman et al., 2010; De Backer et al., 
2010; Fleury et al., 2010; Havn et al., 2010; Olanday et al., 2010; Duangwhae et al., 2010; Yao et al., 2010; Liu et al., 
2010; Oh et al., 2010; Grimbeek, 2010; Sy et al., 2010; DiPietre et al., 2010; Fourchon et al., 2010; Karunyasiri et al., 
2010; Lorenzo et al., 2010; Cano et al., 2010; de Grau, 2010; Brons et al., 2010; Biksi et al., 2010; Holck et al., 2010; Diaz 
et al., 2010; Coll et al., 2010; Miller et al., 2010a; Miyashita et al., 2010a; Suprenant et al., 2010a; Eggen et al., 2010a; 
Kim et al., 2010a; Palacios et al., 2010a; Ehlorsson et al., 2010a; Miyashita et al., 2010b; Suprenant et al., 2010b; Miller et 
al., 2010b; Kim et al., 2010b; Palacios et al., 2010b; Kim et al., 2010c; Kim et al., 2010d; O'Dea et al., 2011; Strugnell et 
al., 2011; Lee et al., 2011; Alberti et al., 2011; Ramis et al., 2011; Nieto et al., 2012; Shelton et al., 2012; Lising et al., 
2012; Toledo et al., 2012; Yu, 2012)
(Reicks et al., 2008; Cardinal, 2008; Dewey et al., 2008; Thacker et al., 2012) 
(Cardinal, 2010; Grechukhin, 2010a; Grechukhin, 2010b; Estrada, 2011; Coll, 2011; Maksimov, 2011; Safiullin et al., 
2011; Young et al., 2011a) 
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Fig. 3. Random and fixed effects models of all included trials for Ingelvac® CircoFLEX™, 
sub-grouped by PRRSV status with a forest plot of the observed mean differences and 95% 
confidence intervals. 
*Barn was used as the unit of treatment allocation.  
†Pen was used as the unit of treatment allocation. 
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Fig. 4. Random and fixed effects models of all included trials for Circumvent® PCV, sub-
grouped by PRRSV status with a forest plot of the observed mean differences and 95% 
confidence intervals.  
†Pen was used as the unit of treatment allocation. 
  
† † † 
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Fig. 5. Random and fixed effects models of all included trials for Suvaxyn® PCV2/Fostera™ 
PCV, sub-grouped by PRRSV status with a forest plot of the observed mean differences and 
95% confidence intervals. 
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Fig. 6. Summary of the risk of bias assessment for all included studies based on the review 
authors’ determination using the Cochrane risk bias assessment tool. (+ = low risk of bias; - = 
high risk of bias; ? = unclear risk of bias). 
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CHAPTER 3 – STUDIES ON PCV2 VACCINATION OF 5-DAY-OLD 
PIGLETS 
 
A paper published in Clinical and Vaccine Immunology [2011, Nov; 18(11): pp. 1865-
1871] 
 
Kevin C. O’Neill, Huigang Shen, Michelle Hemann, Nathan M. Beach, Xiang-Jin Meng, 
Patrick G. Halbur, Tanja Opriessnig 
 
1.  Abstract 
Porcine circovirus type 2 (PCV2) vaccines have become widely used since they 
became available in 2006. It is not uncommon for producers to use PCV2 vaccines in pigs 
younger than what is approved by manufacturers. The objective of this study was to 
determine the efficacy of a chimeric and a subunit PCV2 vaccine administered at 5 or 21 
days of age. Forty-eight PCV2-naïve piglets were randomly divided into six groups of eight 
pigs each. Vaccination was done at day 5 or day 21, followed by triple challenge with PCV2, 
porcine parvovirus (PPV), and porcine reproductive and respiratory syndrome virus 
(PRRSV) at day 49. Vaccinated pigs seroconverted to PCV2 approximately 14 days post-
vaccination and had a detectable neutralizing antibody response by 21 days post-vaccination 
regardless of age at vaccination. At day 49, the pigs vaccinated with the chimeric vaccine had 
significantly higher levels of neutralizing antibodies than the pigs vaccinated with the subunit 
vaccine. After challenge, vaccinated pigs had significantly decreased levels of PCV2 viremia 
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and a decreased prevalence and severity of microscopic lesions compared to the positive-
control group, which had severe lymphoid lesions associated with abundant PCV2 antigen, 
compatible with PCV-associated disease. The results of this study indicate that, under the 
conditions of this study, vaccination of PCV2-naïve pigs at day 5 or day 21 resulted in 
development of a detectable humoral immune response and provided reduction or complete 
protection against PCV2 viremia and PCV2-associated lesions after triple challenge with 
PCV2, PPV, and PRRSV. 
2.  Introduction 
Porcine circovirus (PCV) is a circular, single-stranded, non-enveloped DNA virus 
(46) that can be separated into two main types: PCV type 1 (PCV1) and PCV type 2 (PCV2). 
PCV1 is not associated with disease or lesions in pigs and is commonly considered 
nonpathogenic (47). PCV2 is linked with a variety of clinical disease manifestations 
collectively referred to as PCV-associated disease (PCVAD), including systemic disease or 
postweaning multisystemic wasting syndrome (PMWS) (16), respiratory disease (17), and 
enteric disease (20) in growing pigs. 
PCV2 is prevalent worldwide, and most herds are seropositive (5, 6, 47). From 2005 
to 2006, PCVAD became increasingly problematic in North America, leading to high 
production losses for producers (19). Aggressive vaccination programs initiated in 2006 have 
substantially decreased the prevalence and severity of PCVAD (14, 21). 
U.S. pork producers now have several choices of approved commercial vaccines. 
Two of the commercial PCV2 vaccines commonly used in the United States are a subunit 
vaccine and one is a chimeric vaccine. One of the subunit vaccines (Ingelvac CircoFLEX; 
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Boehringer Ingelheim Vetmedica) is licensed for use in pigs at 3 weeks of age or older, 
provides protection beginning 2 weeks post-vaccination, and has at least a 17-week duration 
of immunity. The inactivated chimeric PCV2 vaccine (formerly Suvaxyn PCV2 from Fort 
Dodge Animal Health, Inc., and now reformulated as Fostera™ PCV from Pfizer Animal 
Health, Inc.) is also licensed for use in pigs 3 weeks of age or older. According to the 
manufacturer, this product provides protection against PCV2 challenge 3 weeks (two-dose 
application) or 6 weeks (one-dose application) post-vaccination for up to 4 months duration. 
This product was voluntarily removed from the market in May 2010 due to concerns 
regarding the inactivation process (13) and was reintroduced to the market in August 2011. 
In the field, coinfections heavily influence the severity and outcome of PCVAD. 
Some of the most severe field case reports of PCVAD describe coinfection of pigs with 
PCV2, porcine parvovirus (PPV), and porcine reproductive and respiratory syndrome virus 
(PRRSV) (7, 8). PPV has been shown to cause stillbirths and mummification in breeding 
herds but is generally considered nonpathogenic in growing pigs (22); however, when pigs 
are co-infected with PCV2 and PPV, this can lead to severe PCVAD in a portion of the pigs 
(1, 8, 22). PRRSV has become endemic and is known to cause abortions in the breeding herd 
and pneumonia in growing pigs (39). When found combined with PCV2 in the field or when 
pigs are experimentally co-infected with PRRSV and PCV2, disease and lesions are often 
quite severe (2, 18, 40). 
A common concern when evaluating a vaccination program, besides the efficacy of 
the vaccine, is the appropriate timing of vaccination to provide maximal protection for the 
pig and convenience of use for the pork producer. Vaccines are commonly labeled for use at 
day 21 or older. Many pig farm managers prefer to vaccinate pigs at day 2 to day 5, which is 
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when they are handling piglets for other reasons. There are concerns, ongoing discussions, 
and debate over whether the pig has a sufficiently mature immune system at this age and if 
passively acquired antibodies interfere with vaccination. Therefore, if vaccination against 
pathogens such as PCV2 is proven to be effective in pigs less than 1 week of age, this 
ultimately could lead to substantial changes in vaccination protocols on many farms. 
The objective of this study was to determine the efficacy of two commercial PCV2 
vaccines, an inactivated chimeric vaccine and a subunit vaccine, at day 5 and day 21, in a 
triple challenge model with PCV2, PPV, and PRRSV. The triple challenge model was used 
to mimic field conditions where coinfections with PCV2, PPV, and PRRSV are commonly 
observed (7, 8, 35, 36). 
3.  Materials and methods 
I.  Animals and housing 
Forty-eight conventional cross-bred pigs were derived from six sows from a breeding 
herd known to be free of PCV2, PRRSV, and PPV as determined by routine serology 
conducted monthly. At 4 days of age, while still on the dam, all pigs were ear tagged and 
randomly assigned to one of six treatment groups within each litter so that at least one pig 
from each sow was in a given treatment group. The pigs were weaned at approximately 14 
days of age and transported to the research facility. Upon arrival at the Iowa State University 
Livestock Infectious Disease Isolation Facility, the pigs were separated into four rooms: one 
room for the negative-control group, one room for the positive-control group, one room for 
both groups receiving the inactivated chimeric vaccine, and one room for both groups 
receiving the subunit vaccine. Pigs were housed in pens on a concrete floor that was cleaned 
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once daily. Each room had separate ventilation systems and one nipple drinker. The 
vaccinated pigs were separated in two pens placed on opposite sides of the room based on 
timing of vaccination at day 5 or day 21. All pigs were fed an age-appropriate diet free of 
animal proteins (excluding whey) and antibiotics (Natures Made; Heartland Co-op, 
Cambridge, IA). 
II.  Experimental design  
The study was approved by the Iowa State University Institutional Animal Care and 
Use Committee (IACUC 11-09-6831-S) and the Institutional Biosafety Committee (IBC 09-
I-0030-A). The 48 pigs were randomly divided into groups of 8 pigs. The timeline of the 
experiment is summarized in Fig. 1. At day 5, 16 pigs were vaccinated with one of two PCV2 
vaccines: an inactivated chimeric vaccine (chimeric-d5) or a viral subunit vaccine (subunit-
d5). Similarly at day 21, 16 pigs were vaccinated with the inactivated chimeric vaccine 
(chimeric-d21) or a subunit vaccine (subunit-d21). Upon arrival to the research facility, blood 
was collected at weekly intervals until termination of the project at week 10. The blood 
samples were collected in serum separator tubes (Becton Dickinson vacutainer; 8.5 ml) and 
centrifuged at 2,000 × g for 10 min at 4°C, and the serum was separated into two aliquots and 
stored at −80°C until testing. All pigs, except for the negative-control group, were inoculated 
with PPV, PRRSV, and PCV2b at day 49, and all pigs were euthanized for necropsy at day 
70. 
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i. Clinical evaluations 
Upon arrival at the research facility the pigs were individually examined and then 
monitored daily for clinical signs of disease, such as inappetence, lethargy, lameness, and 
respiratory disease. 
ii.  Vaccination 
The inactivated chimeric vaccine used in this study was Suvaxyn PCV2 (serial 
number 1861229A; Fort Dodge Animal Health, Inc.). The subunit vaccine was Ingelvac 
CircoFLEX (serial number 309-136; Boehringer Ingelheim Vetmedica). Each of the pigs in 
the vaccinated groups received 2 ml of Suvaxyn PCV2 or 1 ml of Ingelvac CircoFLEX 
vaccine intramuscularly into the right neck via a 0.77-mm 22-gauge needle. Vaccination was 
done at day 5 or day 21. 
iii. PCV2b, PPV, and PRRSV inoculation 
All pigs, excluding the negative-control group, were inoculated at day 49 with 
PCV2b, PPV, and PRRSV. 
iv. PCV2 inoculation 
The PCV2 inoculum consisted of PCV2b isolate NC-16845 (32), which was 
propagated on PK-15 cells to a titer of 104.5 50% tissue culture infective doses (TCID50) per 
ml. PCV2 inoculation was done by administering 1 ml of the inoculum intramuscularly into 
the right neck and slowly dripping 2 ml of the inoculum intranasally (1 ml per nostril) while 
the pig was held in the upright position. 
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v.  PPV inoculation  
The PPV inoculum consisted of a tissue homogenate containing strain NADL-8 at a 
titer of 106.0 TCID50 per ml (25). PPV inoculation was done by slowly dripping 1 ml of 
inoculum intranasally while the pig was held in the upright position. 
vi. PRRSV inoculation 
The PRRSV inoculum consisted of PRRSV isolate ATCC VR2385 (15). PRRSV was 
propagated on MARC-145 cells to the seventh passage at a titer of 105.0 TCID50 per ml. 
PRRSV inoculation was done by slowly dripping 2.5 ml of inoculum intranasally while the 
pig was held in the upright position. 
III.  Serology 
i.  PCV2 
All pig sera, from day 21 to day 70, were tested for anti-PCV2 antibodies by a PCV2 
capsid protein-based enzyme-linked immunosorbent assay (ELISA) as previously described 
(28). A sample-to-positive (S/P) ratio of greater than or equal to 0.2 was considered positive. 
A fluorescent focus neutralization (FFN) assay was performed on serum samples collected 21 
days after vaccination for all vaccinated pigs and at the day of challenge (day 49) for all pigs 
for the detection of neutralizing antibodies, using a previously described method (37). 
ii. PPV 
The anti-PPV IgG antibodies were detected in serum from day 49 and day 70 via a 
hemagglutination inhibition (HI) assay, as previously described (26). 
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iii. PRRSV 
All pig sera from day 49 and day 70 were tested for anti-PRRSV antibodies by 
ELISA (PRRS X3Ab test; IDEXX Laboratories Inc., Westbrook, MA) according to the 
manufacturer's instructions. An S/P ratio of 0.4 was used as the minimum positive cutoff 
value. 
IV. Quantitative real-time PCR assays 
i. Total nucleic acid extraction 
All day 49, day 56, day 63, and day 70 serum samples were extracted using a total 
nucleic acid extraction kit (MagMAX viral isolation kit; Applied Biosystems, Foster City, 
CA) with the KingFisher Flex magnetic particle processor extraction system (Thermo Fisher 
Scientific, Waltham, MA). 
ii. PCV2 
PCV2 viremia was determined by the detection of the presence and amount of viral 
DNA in serum samples from all pigs on day 49, day 56, day 63, and day 70 via quantitative 
PCR using the same primers and probes as previously described (42). This was done in a 
7500 fast real-time PCR system (Applied Biosystems, Foster City, CA). A final 25-l 
volume containing 2.5 l of extracted DNA was processed under the following thermocycler 
conditions: 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 
min at 60°C. 
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iii. PPV 
Viremia for PPV was determined by detection of the presence and amount of PPV 
DNA in serum samples collected on day 49, day 56, day 63, and day 70 via quantitative real-
time PCR as previously described (42). The final volume of the reaction mixture was 25 l, 
which consisted of 12.5 l of commercially available master mix (TaqMan Universal PCR 
master mix; PE Applied Biosystems), 2.5 l of DNA from either sample extraction or 
standard, 1 l (0.4 M) of each primer, and 0.5 l (0.2 M) of the probe. The thermocycler 
conditions were as follows: 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s 
at 95°C and 1 min at 60°C. 
iv. PRRSV 
Quantitative real-time reverse transcription-PCR (RT-PCR) for PRRSV viremia was 
performed on serum samples collected on day 56, day 63, and day 70 using the TaqMan NA 
and EU PRRSV reagents (Applied Biosystem) as previously described (42). PRRSV RNA 
presence and quantity were identified with real-time RT-PCR by utilizing TaqMan NA and 
EA PRRSV reagents (Applied Biosystems) with a final volume of 25 l, containing 12 l of 
2× multiplex RT-PCR buffer, 2.5 l of 10× PRRSV primer probe mix, 1.25 l of 20× 
multiplex enzyme mix, 0.75 l of nuclease-free water, and 8 l of either PRRSV RNA from 
the previous extraction or standards. The thermocycler conditions were as follows: 10 min at 
45°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 70 s at 60°C. 
V. Necropsy 
All pigs were humanely euthanized with an intravenous overdose of pentobarbital 
sodium (Fatal Plus; Vortech Pharmaceuticals, Dearborn, MI) at day 70. The total amount of 


 
macroscopic lung lesions was estimated and scored (0 to 100% of the lung affected) as 
previously described (15). The sizes of lymph nodes (score range from 0 to 3: 0 [normal], 1 
[two times the normal size], 2 [three times the normal size], and 3 [four times the normal 
size]) were estimated as described previously (29). Sections of lung, heart, liver, lymph 
nodes (tracheobronchial, superficial inguinal, external iliac, mediastinal, and mesenteric), 
spleen, kidney, ileum, colon, tonsil, and thymus were collected, placed into 10% neutral 
buffered formalin, and routinely processed for histological examination. 
VI. Histopathology and immunohistochemistry 
Microscopic examination of tissues was done by a veterinary pathologist who was 
blinded to the treatment groups. Lung sections were scored for presence and severity of 
interstitial pneumonia, with scores ranging from 0 to 6 (0 [normal]; 6 [severe diffuse]) (15). 
Sections of heart, liver, kidney, ileum, and colon were evaluated for the presence of 
lymphohistiocytic inflammation and scored on a scale of 0 (none) to 3 (severe). Lymphoid 
tissues, including lymph nodes, tonsil, and spleen, were evaluated for the presence of 
lymphoid depletion, with scores ranging from 0 (normal) to 3 (severe lymphoid depletion) 
and scores for histiocytic replacement of follicles ranging from 0 (normal) to 3 (severe) (34). 
Immunohistochemistry (IHC) for PCV2 was performed on formalin-fixed, paraffin-
embedded tissue sections by using a rabbit polyclonal antibody as previously described (45). 
Tissues evaluated included tonsil, spleen, lymph nodes (mesenteric, mediastinal, 
tracheobronchial, external inguinal, and subiliac), and thymus. PCV2 antigen scoring was 
performed in a blinded fashion, and scores ranged from 0 (no signal) to 3 (more than 50% of 
lymphoid follicles containing cells with PCV2 antigen staining) (34). 
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The overall PCV2-associated lesion scores were determined as previously described 
(34). A combined scoring system for each lymphoid tissue that ranged from 0 to 9 (lymphoid 
depletion score, 0 to 3; histiocytic replacement score, 0 to 3; PCV2 IHC score, 0 to 3) was 
used. The scores (lesions and PCV2 IHC) of the seven lymphoid tissues (lymph node pool × 
5, spleen, and tonsil) were added together and divided by 7. The lymph node pool consisted 
of one section each of tracheobronchial, superficial inguinal, external iliac, mediastinal, and 
mesenteric lymph nodes. Pigs were grouped into four categories based on overall 
microscopic lymphoid lesion score: normal (score of 0), mild (score of 1 to 3), moderate 
(score of 4 to 6), and severe (score of 7 to 9). A pig was diagnosed with PCVAD if the mean 
lymphoid microscopic lesion severity score was severe (score of 7 to 9). The mean group 
overall lymphoid score was calculated and compared between groups. 
VII. Statistical analysis 
The data were statistically analyzed by performing a one-way analysis of variance 
(ANOVA) with JMP software version 9.0.0 (SAS Institute, Cary, NC). The significance level 
was P < 0.05, followed by pairwise testing using the Tukey-Kramer adjustment to identify 
the groups that were different. All real-time PCR data were log10 transformed prior to 
analysis. The percentage of reduction of PCV2 viremia in vaccinated groups compared to the 
non-vaccinated positive-control group was calculated as follows: 100 − [(100 × mean log10 
genomic copies per ml of serum in vaccinated animals)/(mean log10 genomic copies per ml of 
serum in positive-control animals)]. Nonrepeated measures, such as histopathology data, 
were assessed using a nonparametric Kruskal-Wallis ANOVA. If a nonparametric ANOVA 


 
test was significant (P < 0.05), then Wilcoxon tests were used to assess the differences of 
pairs of groups. Differences in incidence were evaluated by using Fisher's exact test. 
4. Results 
I. Clinical disease 
After challenge, triple-challenged pigs in all groups developed mild to severe 
respiratory disease characterized by sneezing, increased respiratory rates, and clear nasal 
discharge. A portion of the triple-challenged pigs also became lethargic. 
II. Seroconversion against PCV2, PPV, and PRRSV 
i. PCV2 
The negative-control pigs remained seronegative until termination of the study (Fig. 2 
A). Seroconversion to PCV2 in the vaccinated groups was similar for the day 5 (Fig. 2B) and 
day 21 (Fig. 2C) groups. By 14 days post-vaccination, 2/8 subunit-d5, 3/8 subunit-d21, 7/8 
chimeric-d5, and 8/8 chimeric-d21 animals had seroconverted; by 21 days after vaccination 
all vaccinated pigs except 2/8 subunit-d21 animals had seroconverted; by 28 days after 
vaccination all vaccinated pigs were seropositive for PCV2. There was a trend to lower levels 
of detectable anti-PCV2 IgG in pigs vaccinated with the subunit vaccine compared to those 
vaccinated with the chimeric vaccine, and this was independent of age of vaccination (Fig. 
2B and C). The mean amounts of neutralizing antibody levels 21 days post-vaccination were 
similar in pigs vaccinated at day 5 (mean group log10 titers of 1.84 ± 0.16) (± standard error 
[SE]) and day 21 (1.56 ± 0.12); however, there was a significant difference when the data 
were analyzed by product (2.01 ± 0.14 for the chimeric vaccine and 1.39 ± 0.11 for the 
subunit vaccine) 
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As expected, when the data were evaluated by day of age rather than by days after 
vaccination, vaccination at day 5 resulted in significantly (P < 0.05) higher anti-PCV2 IgG 
levels from day 21 until day 42; however, there were no differences between the day 5- and 
day 21-vaccinated groups thereafter (Fig. 2A). At day 21, anti-PCV2 IgG was detected in 
25% (2/8) of the subunit-d5 pigs and 87.5% (7/8) of the chimeric-d5 pigs. The prevalence of 
seropositive pigs was 100% at day 28 for the day 5-vaccinated pigs and 18.8% (3/16) for the 
day 21-vaccinated pigs. All pigs in these groups were seropositive for PCV2 by day 42. 
Regardless of timing of vaccination, the chimeric vaccine induced significantly (P < 0.05) 
higher levels of neutralizing antibodies at day 49 than the subunit vaccine, with mean group 
log10 titers of 2.38 ± 0.18 for the chimeric vaccine compared to 1.82 ± 0.12 for the subunit 
vaccine. Positive-control pigs started to seroconvert by day 63 (62.5%; 5/8 pigs) and day 70 
(75%; 6/8 pigs) as detected by ELISA. 
ii. PPV 
All groups were negative for anti-PPV antibodies on the day of challenge (day 49), 
and the non-challenged negative controls remained negative until day 70. All pigs challenged 
with PPV seroconverted by day 70; however, 2/8 positive-control pigs had noticeably lower 
titers (1:2,048) than all other pigs (1:4,096 to >16,384). Overall, the mean group PPV titers 
of the PPV-challenged animals were not different among treated groups (data not shown). 
iii. PRRSV 
All pigs in all groups were negative for anti-PRRSV IgG on the day of challenge (day 
49), and the non-challenged negative controls remained negative until day 70. The majority 
of the pigs challenged with PRRSV seroconverted by day 70, with the exception of 2/8 
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positive-control pigs. Overall, the mean group anti-PRRSV IgG S/P ratios of the PRRSV-
challenged pigs were not different among groups (data not shown). 
III. PCV2, PPV, and PRRSV viremia 
i. PCV2 
All pigs were negative for PCV2 DNA at the day of challenge (day 49), and the 
negative-control pigs remained negative for PCV2 DNA in serum until termination of the 
study at day 70. The prevalence and the log10 mean group amount of PCV2 DNA in the 
challenged groups are summarized in Table 1. All vaccinated groups had significantly (P < 
0.05) smaller amounts of PCV2 DNA in serum than the positive-control group. When the 
data were divided based on age of vaccination, no evidence of an effect of age at vaccination 
on PCV2 viremia was seen. However, pigs vaccinated with the chimeric vaccine had 
significantly lower mean amounts of PCV2 genomic copies in serum samples on day 63 (P = 
0.021) and day 70 (P = 0.03) than those vaccinated with the subunit vaccine. After challenge, 
PCV2 viremia was reduced by 75.4% to 100% in the vaccinated groups compared to the 
positive-control group. 
ii. PPV 
All pigs were negative for PPV DNA at the day of challenge (day 49), and the 
negative-control pigs remained negative until the termination of the study. The prevalence of 
PPV DNA positive pigs at day 56 was 100% for subunit-d5 and subunit-d21, and it was 
88.9% (7/8) for the chimeric-d5, chimeric-d21, and the positive-control groups. The overall 
prevalence rate of PPV DNA-positive animals was 68.8% (33/48) by day 63 and 20.8% 
(10/48) by day 70, with no significant differences among groups. 
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iii.  PRRSV 
All pigs were negative for PRRSV RNA at the day of challenge (day 49), and the 
negative-control pigs remained PCR negative throughout the study. PRRSV RNA was 
detected in all PRRSV-challenged pigs on day 56, day 63, and day 70 without significant 
differences in the mean group PRRSV RNA levels among the challenged groups, regardless 
of vaccination status. 
IV. Gross lesions 
There were no visible gross lesions in the non-infected control pigs. A portion of the 
triple-challenged pigs, regardless of vaccination status, had moderate to severe mottled, tan-
colored, consolidated areas of lung tissue involving up to 51% of the lung surface. A portion 
of the pigs had lymph nodes that were up to three times the normal size. There were no 
significant differences in gross lesions between challenged pigs. 
V. Microscopic lesions and presence of PCV2 antigen in tissues  
The majority of the pigs developed mild to severe interstitial pneumonia lesions 
characterized by thickening of alveolar septa by macrophages and lymphocytes and mild to 
severe type 2 pneumocyte hypertrophy and hyperplasia. The mean group interstitial 
pneumonia scores ranged from 3.0 ± 0.1 to 3.6 ± 0.4 in the triple-challenged groups and were 
significantly higher (P < 0.05) than for the negative-control group (0.8 ± 0.1). Lymphoid 
lesions, if present, were characterized by mild to severe lymphoid depletion and mild to 
severe histiocytic replacement of lymphoid follicles. 
The prevalence rates of PCV2 antigen and overall lymphoid lesion scores for the 
different groups are summarized in Table 2. The majority of vaccinated pigs had no 
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remarkable lesions and were considered normal. Individual vaccinated pigs (7/32) had an 
overall lesion score of 1 or 2. In the positive-control group, 25% (2/8) of the pigs had 
microscopic lesions compatible with PCVAD associated with abundant amounts of PCV2 
antigen and an overall lymphoid score of 9; 37.5% (3/8) of the pigs had moderate lymphoid 
lesions; the remaining 37.5% (3/8) of the pigs had no to mild lymphoid lesions. 
5. Discussion 
The main objective of this study was to determine the efficacy of PCV2 vaccination 
at an earlier age than recommended by the vaccine manufacturers. Several research groups 
have studied the efficacy of commercial PCV2 vaccines in pigs singularly infected with 
PCV2 (30, 31) or in pigs concurrently infected with multiple pathogens (33, 42). In all 
previous studies, vaccination was done according to the manufacturer's label instructions. To 
our knowledge, this is the first controlled experimental study to test the efficacy of 
commercial vaccines used at less than 3 weeks of age in a manner not approved by the 
manufacturer; however, this regimen mimics what is commonly now done in the field in the 
United States. Many producers prefer to vaccinate with a single-dose PCV2 product while 
piglets are undergoing castration, iron shots, tail docking, and teeth clipping between 2 and 5 
days of age. However, there is concern that the immune system may not be mature enough to 
effectively respond to the vaccinations, potentially resulting in decreased vaccine efficacy 
and duration of immunity. To evaluate the benefits and shortcomings of early vaccination, 
this study entailed use of piglets blocked by litter and randomly assigned to early vaccination 
(day 5), regular vaccination (day 21), or no-vaccination (positive- and negative-control) 
groups. 
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After challenge, PCV2 viremia and associated lesions were similarly reduced in all 
vaccinated pigs regardless of timing of vaccination, indicating that day 5 pigs are capable of 
mounting a protective immune response. Vaccinated pigs were protected from development 
of PCV2-associated lesions independent of timing of vaccination, further indicating that both 
day 5 and day 21 vaccination protocols with either vaccine were effective. The pig immune 
system is unique in many ways that may be responsible for its ability to develop protective 
immunity from early vaccination. These factors include the full-length complementarity-
determining region 3 (CDR3) of the heavy chain of immunoglobulin (4), limited genetic 
combinatorial pre-immune repertoire development (4), and the absence of true gene 
conversion sometimes seen in other species (44). The above-mentioned characteristics of the 
pig immune system combined with the results of this study demonstrate that the 5-day-old 
suckling pig is indeed capable of mounting a protective immune response against PCV2 
challenge. 
The current study was done in PCV2-naïve pigs; however, under field conditions 
most pigs that have suckled will be seropositive due to the ubiquitous nature of PCV2 and 
high levels of anti-PCV2 antibodies in colostrum. Interference with vaccination against swine 
influenza virus associated with the presence of passively acquired antibodies has been 
documented (3, 23, 27, 38); however, evidence of passive antibody interference with PCV2 
vaccination has not been confirmed under experimental conditions (30). Furthermore, PCV2 
vaccines have been highly effective in the field, and almost all pigs are seropositive to PCV2 
at the time of PCV2 vaccination (9, 19, 21, 41). In experimental PCV2 challenge models, 
outcomes are often similar between vaccine treatment groups (11, 24), and conclusions often 
lack power. Passively acquired antibodies in many instances decrease PCV2 viremia and 
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prevent the development of clinical disease under controlled experimental conditions. PCV2 
viremia and expression of clinical disease are often the main outcomes used for vaccine 
efficacy comparisons; however, when using animals with maternally derived anti-PCV2 
antibodies, a much larger sample size may be required to demonstrate differences. Although 
the antibody-negative status of the pigs in the current study did not necessarily mimic what 
occurs with the majority of pigs in the field, studies performed in PCV2 antibody-free and 
PCV2 virus-free pigs are an important first step to increasing our understanding of potential 
advantages and disadvantages of early vaccination regimens. 
To determine if there were differences in the efficacy of one vaccine over another, 
two different products were used side by side in this study. Several previous studies had been 
performed to determine the efficacy of PCV2 subunit vaccines and chimeric PCV2 vaccines 
(10, 12, 43). In these studies, vaccinated animals were shown to have strong antibody 
responses associated with decreased PCV2 viremia after challenge. Similarly, in our study 
the vaccinated animals, regardless of the type of PCV2 vaccine used, all developed a 
detectable antibody response and protective immunity as evidenced by significantly 
decreased PCV2 viremia and a decreased incidence and severity of lesions compared to the 
positive-control group. However, pigs vaccinated with the chimeric product had a stronger 
anti-PCV2 IgG response that was independent of age at vaccination and a lower prevalence 
of PCV2 viremic animals at day 63 and day 70 than pigs vaccinated with the subunit product. 
Moreover, and similar to a previous study using single-dose vaccination (42), vaccination 
with the chimeric product was associated with production of a stronger neutralizing antibody 
response than vaccination with the subunit vaccine. 
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In summary, under the conditions of this study, vaccination with chimeric or subunit 
PCV2 vaccines at 5 or 21 days of age induced a protective immune response in PCV2-naïve 
pigs as demonstrated by development of anti-PCV2 antibodies and reductions of PCV2 
viremia and PCV2-associated lesions in a triple challenge model with PCV2, PPV, and 
PRRSV. 
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Table 1. Prevalence and mean log10 PCV2 DNA in pigs challenged with PCV2 at age 49 
days. 
Group Prevalence (mean level ± SE)a of log10 PCV2 DNA on day:  
56 63 70 
Subunit – d21 1/8 (0.7 ± 0.7)A  3/8 (1.6 ± 0.8)A,B 1/8 (0.5 ± 0.5)A 
Subunit – d5 0/8 (0.0)A  4/8 (2.3 ± 0.9)A 3/8 (1.5 ± 0.7)A 
Chimeric – d21 1/8 (0.6 ± 0.6)A  0/8 (0.0)B 0/8 (0.0)A 
Chimeric – d5 0/8 (0.0)A  0/8 (0.0)B 0/8 (0.0)A 
Positive Controls 7/8 (4.1 ± 0.6)B  8/8 (7.1 ± 0.3)C 8/8 (6.1 ± 0.6)B 
aDifferent superscript capital letters (A, B, and C) within a column indicate significantly (P < 
0.05) different amounts of group mean PCV2 DNA. 
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Table 2. Lymphoid depletion score and prevalence of PCV2 antigen in lymphoid tissues as 
determined by IHC. 
Group Overall lymphoid lesion 
score (mean ± SE)a 
Prevalence of PCV2 
antigen 
Subunit – d21 0.11 ± 0.1A 1/8 
Subunit – d5 0.38 ± 0.2A 2/8 
Chimeric – d21 0.09 ± 0.09A 0/8 
Chimeric – d5 0.30 ± 0.2A 2/8 
Negative Controls 0.0 ± 0.0A 0/8 
Positive Controls 4.59 ± 1.1B 7/8 
aSignificant differences among groups are indicated by different superscript capital letters (A 
and B). 
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Fig. 1. Experimental design. All serum samples collected were tested for the presence of 
PCV2 antibody. Samples from day of age 49, 56, 63, and 70 were tested for the presence and 
amount of PCV2 DNA and PPV DNA. Samples from day 56, day 63, and day 70 were tested 
for the presence and amount of PRRSV RNA. Samples from day 49 and day 70 were tested 
serologically for PRRSV and PPV. 
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Fig. 2. (A) Mean group PCV2 ELISA S/P ratios (± SE) on serum collected from piglets 
vaccinated at day of age 5 (d5) or 21 (d21) or non-vaccinated and challenged with PCV2, 
PPV, and PRRSV at day 49, which corresponds to 44 days after vaccination for day 5 piglets 
and 28 days after vaccination for day 21 piglets. An S/P ratio of 0.2 or greater was 
considered seropositive. Significant differences among groups on a certain day are indicated 

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by different letters (A, B, and C). (B) Comparison of subunit-d5 and chimeric-d5 pigs at 
different days post-vaccination. Significant differences among groups on a certain day are 
indicated by an asterisk. (C) Comparison of subunit-d21 and chimeric-d21 pigs at different 
days post-vaccination. Significant differences among groups on a certain day are indicated by 
an asterisk. 
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1. Summary 
 The objectives of this study were to further understand vertical transmission of 
porcine circovirus type 2 (PCV-2) and the effect of dam vaccination on PCV-2 viraemia in 
newborn piglets. Randomly selected sows from each of two breeding herds were designated 
as non-vaccinated or vaccinated groups. A commercial inactivated PCV-2 vaccine was 
administered at weaning and 18 days later to half of the sows on each farm. At parturition, 
colostrum was collected from 70 dams on each farm and post- (Farm 1) or pre-suckle blood 
(Farm 2) was collected from five randomly selected piglets per litter. Colostrum samples had 
an anti-PCV-2 antibody prevalence of 98.5% (135/137) with significantly (p=0.0039) higher 
concentrations in vaccinated dams. Among piglets, 43.9% (301/685) were seropositive for 
PCV-2 and 11.7% (80/686) were PCV-2 DNA positive. All of the PCV-2 DNA positive 
samples were further characterized and 28 were PCV-2a, 28 PCV-2b, and 5 mixed PCV-2a 
and PCV-2b infection. The prevalence of PCV-2 DNA in piglets was lower (0.7% to 22.8%) 
compared to previous studies (44.8% to 90%) indicating a change in PCV-2 ecology likely 
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due to wide use of vaccination. Under the study conditions, dam vaccination reduced PCV-2 
viraemia in the offspring with colostrum access. 
2. Introduction 
Porcine circovirus (PCV) type 2 (PCV-2) is a non-enveloped, single-stranded circular 
DNA virus (Tischer and others 1982) and along with PCV type 1 (PCV1) belongs to the 
family Circoviridae. PCV-2 is highly prevalent in the global swine population (Tischer and 
others 1986, Dulac and Afshar 1989, Edwards and Sands 1994, Segalés and others 2008) and 
can be divided into several genotypes of which PCV-2b is the predominant genotype 
(Cheung and others 2007, Gagnon and others 2007, Olvera and others 2007, Dupont and 
others 2008, Segalés and others 2008). 
PCV-2 is linked to several clinical disease manifestations referred to as PCV-
associated diseases (PCVAD) (Opriessnig and others 2007). Clinical PCVAD may manifest 
as postweaning multisystemic wasting syndrome (PMWS) (Harding and Clark 1997), 
porcine respiratory disease (Harms and others 2002), enteric disease (Kim and others 2004), 
reproductive failure (West and others 1999) and less often as porcine dermatitis and 
nephropathy syndrome (PDNS) (Choi and Chae 2001). The ubiquitous nature of PCV-2 can 
be attributed to its many routes of transmission: oronasal (Shibata and others 2003), fecal 
(Shibata and others 2003), seminal (Larochelle and others 2000), trans-placental (Park and 
others 2005), and colostral (Shibata and others 2006). Vaccination of growing pigs against 
PCV-2 has been shown to be highly effective in decreasing the prevalence and severity of 
PCVAD (Kixmöller and others 2008, Gillespie and others 2009).  



Recently, much attention has been given to PCV-2 prevention in growing pigs 
through vaccination of the breeding herd. It has been shown that PCV-2 infection of dams 
can result in viraemia and in utero infection of the piglets (West and others 1999, O'Connor 
and others 2001, Ladekjær-Mikkelsen and others 2001). Interestingly, a substantial number 
of piglets are born viraemic and appear to be healthy (Shen and others 2010a). In a recent 
field investigation in the USA, the frequency of vertical PCV-2 transmission in five 
commercial breeding herds demonstrated that the overall PCV-2 DNA prevalence was 69.5% 
(89/128) in sows and 44.8% (226/504) in neonates (Shen and others 2010a). Another 
research group determined that prevalence rates of PCV-2 viraemic newborn pigs on three 
farms ranged from 58% to 90% (Dvorak and others 2010) 
The objectives of this study were to determine if the previous results of high levels of 
PCV-2 viraemia in dams and piglets occurs in breeding facilities in Iowa in 2011 and if dam 
vaccination has an effect on vertical PCV-2 transmission rates. 
3. Materials and methods 
I.  Farms 
Farm 1 was part of a multi-site, breed-to-wean facility that housed approximately 
2,400 breeding age females. Dams were inseminated via artificial insemination (AI) using 
semen from a boar stud located in Iowa. Farm 2 was an individual breeding herd with 
approximately 2,700 breeding age females managed in similar fashion as Farm 1. All gilts 
and sows on both farms received a pre-farrow Escherichia coli vaccine. All breeding stock 
was routinely vaccinated against porcine parvovirus, leptospirosis, and Erysipelothrix 
rhusiopathiae at weaning, and dams on Farm 2 were also vaccinated against swine influenza 
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virus. Both herds, although serologically positive for porcine reproductive and respiratory 
syndrome virus (PRRSV), were considered PRRSV stable, and produced PRRSV RNA 
negative piglets. Incoming gilts or resident breeding animals were not vaccinated against 
PCV-2. PCV-2 vaccination of breeding stock at weaning age prior to arrival in the breeding 
herds cannot be ruled out.   
II. Experimental design, vaccination, sample collection and reproductive parameters 
All study procedures were approved by the Iowa State University Institutional 
Animal Care and Use Committee (IACUC# 11-09-6831-S). Calculation of the necessary 
sample size was derived from the assumption of a 50% prevalence of PCV-2 in breeding 
females similar to a previously described study (Shen and others 2010a). It was determined 
that on each farm, 35 dams in each treatment group were needed to detect a difference in 
effect. Therefore, on each of the two farms approximately 100 sows with concurrent oestrus 
cycles were blocked by parity (1-10) to allow for an equal parity representation, and divided 
into two groups of approximately 50 vaccinated and 50 non-vaccinated dams. Although 
samples were collected from only 35 sows, initially 50 sows were assigned to each group to 
assure that 35 sows would be farrowing at the time the research team visited the farm to 
collect samples. This allowed for any losses due to failure to conceive or missed or 
unsupervised farrowings. As soon as samples from 35 litters were collected, collection was 
immediately stopped and samples and data from the remaining litters were not collected. 
The vaccinated group was vaccinated with Suvaxyn PCV (Fort Dodge Animal Health 
Inc., serial number: 1861229A) at weaning. The vaccine was administered in a 2 ml dose 
intramuscularly in the right neck. A second booster vaccination was administered 18 days 
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later using 1 ml intramuscularly at the same site. All sows were routinely inseminated during 
their first oestrus cycle after weaning.  
Among the selected sow parity blocks, for each treatment group 35 sows were 
arbitrarily selected at the time of farrowing. At parturition, colostrum was collected from the 
dams and blood was collected from five arbitrarily selected healthy appearing piglets from 
each litter prior to colostrum uptake. Based on evaluation of swine total IgG optical density 
(OD) values in piglet sera, it was concluded that sample collection occurred after colostrum 
on Farm 1 and prior to colostrum uptake on Farm 2. The piglets on Farm 1 were selected by 
farm workers and brought into a different room to the research team members who were 
responsible for blood collection. Blood was collected from the umbilical cord or the jugular 
vein. To avoid cross contamination during sample collection, gloves were changed between 
animals and tubes were opened, closed and stored by people not handling the animals. On 
Farm 2, piglet selection and samples collection was solely done by research team members. 
Blood was collected only from the jugular vein. The final sample numbers obtained are 
summarized in Table 1. All samples were tested for the presence of anti-PCV-2 IgG via 
serology, and presence, quantity, and subtype of PCV-2 DNA through real-time PCR assays. 
At farrowing, litter characteristics were noted for all dams included in this study.  
III. Serology 
All colostrum and serum samples were tested for anti-PCV-2 antibodies using a 
previously described ORF2-based enzyme linked immunosorbent assay (ELISA) 
(Nawagitgul and others 2002). A sample with a sample-to-positive (S/P) ratio equal or 
greater than 0.2 was considered positive. Selected samples (n=44) obtained from Farm 1 
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were also tested with the SERELISA PCV2 Ab Mono Blocking ELISA kit (Synbiotics; 
Pfizer, Inc), according to manufacturers’ instructions. 
All piglet serum samples were also tested by an in-house swine total IgG ELISA. 
Briefly, microtiter plates (Nunc; Thermo Fisher Scientific Inc) were coated with 0.5 g/ml of 
a goat anti-swine IgG (Fc) antibody (Fitzgerald) in phosphate-buffered saline (PBS) and were 
incubated overnight at room temperature. After three washes with PBS containing 0.05% 
Tween 20, the plates were blocked with 1% bovine serum albumin (Jackson 
ImmunoResearch, Inc) for 2 h at room temperature. The serum samples were diluted 1:100 
with PBS containing bovine serum albumin (Jackson ImmunoResearch, Inc), were placed on 
the plates, and were incubated for 45 min at 37°C. After a washing step, a 1:40,000 dilution 
of peroxidase-conjugated 125 goat anti-swine IgG (Jackson ImmunoResearch, Inc) was 
added to each well and incubated at 37°C for 30 min. After another washing step, 
tetramethylbenzidine-hydrogen peroxide (TMB) chromogenic substrate (KPL) was added to 
each well. After 15 min at room temperature the reaction was terminated by adding 50 l of 
2.5 M sulfuric acid to each well and the absorbance at 450 nm was measured using a 
spectrophotometer. As assay controls, piglets sera with known suckle or pre-suckle status 
were included. The piglet mean OD readings were compared across farms. 
IV. Detection of PCV-2 DNA 
i. DNA extraction.  
DNA from all serum and colostrum samples was obtained by using a commercially 
available extraction kit (QIAamp DNA Blood Kit; Qiagen) according to the manufacturers’ 
specifications. 
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ii. General PCV-2 real-time PCR.  
PCV-2 DNA was detected using previously described primers and a probe targeting 
ORF1 of PCV-2 (Shen and others 2010b) in a 7500 Fast Real-Time PCR system (ABI). The 
reaction consisted of a total volume of 25 µl containing 2.5 µl of extracted DNA and 
processed in the following cycles: one cycle of 2 min at 50°C, one cycle of 10 min at 95°C, 
40 cycles of 15 sec at 95°C, and 40 cycles of 1 min at 60°C. A sample with a cycle threshold 
(CT) value greater than 40 was considered negative. 
iii. PCV-2a/b multi-plex PCR.  
Differentiation between PCV-2a and PCV-2b was achieved by using a previously 
described multiplex real-time PCR assay targeting signature motif located in ORF2 of PCV-2 
(Opriessnig and others 2010) with a total reaction volume of 25µl consisting of 12.5 µl of 
commercially available master mix (TaqMan Universal PCR master mix), 5 µl of DNA, 0.4 
µM of each primer, and 0.2 µM of each probe. The cycling conditions were as follows: one 
cycle of 2 min at 50°C, one cycle of 10 min at 95°C, 40 cycles of 15 sec at 95°C, and 40 
cycles of 1 min at 60°C. A sample with a CT value greater than 40 was considered negative.   
V. Statistical analysis 
 Quantitative real-time PCR results were log10 transformed before analysis. Data 
analysis was performed using JMP software version 9.0.0 and SAS software version 9.2 
(SAS Institute) and a p-value less than 0.05 was considered to indicate statistical 
significance. For ELISA S/P ratios, a linear mixed model was used with “farm”, “parity” and 
“farm by vaccination status interaction” as fixed effects. For binary outcomes (PCV-2 
antibody prevalence or DNA prevalence), Cochran-Mantel-Haenszel statistics were used to 
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assess association between “vaccination status” and “PCV-2 prevalence rates” stratified by 
parity and farm. Serological results for each farm were analyzed using pairwise t-tests. 
Differences in prevalence between groups were determined by Fisher's exact test. 
4. Results 
I.  Litter characteristics 
Among the selected litters in Farm 1, the average number of liveborn pigs (se) was 
12.2 (0.3), the average number of stillborn pigs was 1.2 (0.2), and the average number of 
mummified fetuses was 0.4 (0.2). Among the selected litters in Farm 2, the average number 
of liveborn pigs was 11.8 (0.4), the average number of stillborn pigs was 0.8 (0.2), and the 
average number of mummified fetuses was 0.2 (0.1). There were no differences (p>0.05) 
between vaccinated and non-vaccinated dams (Table 2). 
II. Total IgG levels in piglet sera 
 The anti-IgG OD values from Farm 1 piglets were similar to samples obtained from 
piglets collected after suckling whereas those from Farm 2 piglets were similar to samples 
obtained from piglets prior to suckling (data not shown). Farm 1 piglets had significantly 
(p<0.0001) higher mean OD values (1.32±0.02) compared to Farm 2 piglets (0.63±0.01). 
III.  Prevalence of anti-PCV-2 IgG and mean group ELISA S/P ratios 
Overall, all vaccinated dams (70/70) and 97% of the non-vaccinated dams (65/67) 
had detectable anti-PCV-2 IgG in colostrum. Vaccinated dams had significantly (p=0.0039) 
higher group mean S/P values compared to non-vaccinated dams (1.75±0.08 versus 
1.41±0.07). There were no significant differences in prevalence rates of PCV-2-antibody 
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positive dams. The results for vaccinated and non-vaccinated dams by farm are summarized 
in Table 3.  
Among piglets across both farms, 44.5% (153/344) of those derived from vaccinated 
dams and 43.4% (148/341) of the piglets derived from non-vaccinated dams had detectable 
anti-PCV-2 IgG in serum. The results for piglets derived from vaccinated and non-vaccinated 
dams separated by farm are summarized in Table 3. Due to the high numbers of PCV-2 
seropositive piglets (88.1%; 297/337) on Farm 1, a portion of the seropositive samples 
(n=44) was tested with a second commercial available ELISA and similar results were 
obtained (data not shown). Farm 1 piglets obtained from vaccinated dams had significantly 
(p<0.001) higher anti-PCV-2 IgG than piglets derived from non-vaccinated dams (Table 3) 
which was independent of total IgG levels (p=0.203). On Farm 2, only 1.1% (4/348) of the 
piglets were seropositive. Due to the low numbers of seropositive pigs, differences in mean 
group S/P ratios between piglets from vaccinated and non-vaccinated sows were not 
observed (Table 3).  
The litter distribution of PCV-2 seropositive pigs separated by farm is summarized in 
Table 4. There were no differences in prevalence of seropositive pigs between litters from 
vaccinated or non-vaccinated dams within farms. 
IV. Prevalence of PCV-2 DNA 
Overall, PCV-2 DNA was identified in 2.9% (2/67) of colostrum samples from non-
vaccinated dams but was not detected in colostrum from any of the 70 vaccinated dams. The 
prevalence of PCV-2 DNA separated by treatment status and farm is summarized in Table 3. 
PCV-2 DNA was identified in 5.9% of the colostrum samples obtained from non-vaccinated 
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Farm 1 sows (2/34). PCV-2 DNA was not detected in colostrum from any of the vaccinated 
dams in Farm 1 or in colostrum from any of the vaccinated or non-vaccinated dams in Farm 
2 (Table 3).  
The combined Farm 1 and Farm 2 results indicated that PCV-2 DNA was detected in 
14.9% (51/342) of the serum samples obtained from piglets derived from non-vaccinated 
dams and in 8.4% (29/344) of the samples obtained from piglets derived from vaccinated 
dams. Among PCV-2 positive samples, 28 were identified as PCV-2a, 28 were PCV-2b, five 
had a mixed PCV-2a and PCV-2b infection and the subtype was not determinable in 19 PCR 
positive piglets. On farm 1, piglets derived from vaccinated dams had a significantly 
(p<0.001) lower prevalence of PCV-2 DNA positive pigs compared to piglets obtained from 
non-vaccinated dams (Table 3). The litter distribution of PCV-2 DNA positive pigs separated 
by farm is summarized in Table 4. Overall, the prevalence of litters containing at least 1 to 3 
PCV-2 DNA positive pigs was significantly (p=0.036) higher for litters from non-vaccinated 
sows (41.3%; 29/70) compared to litters obtained from vaccinated sows (28.6%; 20/70). On 
the individual farm level, for Farm 1 the prevalence of litters without PCV-2 DNA positive 
pigs was higher (p<0.01) if the pigs were born to vaccinated dams. Conversely, the 
prevalence of litters containing 2-3 PCV-2 DNA positive pigs was lower (p<0.05) if the pigs 
were born to vaccinated dams.  
5. Discussion  
This study aimed to confirm the previously determined high rates of vertical PCV-2 
transmission and to evaluate potential benefits of PCV-2 vaccination of breeding herds on 
vertical PCV-2 transmission. To address these aims, two independent farrowing facilities that 
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were not currently utilizing PCV-2 vaccination in their breeding stock were identified and a 
portion of the dams were vaccinated with a commercially available inactivated vaccine.  
Due to results from a previous study where we found comparable incidence of PCV-2 
detection in serum (47.2%, 59/125) and colostrum samples (40.8%, 51/125) (Shen and others 
2010a), to simplify the sample collection procedure in this study, only colostrum was 
collected and tested to determine the dam PCV-2 status. In this study, PCV-2 DNA was 
detected in 1.5% (2/137) of the colostrum samples which is lower compared to previous 
findings perhaps indicating a low grade PCV-2 infection in the selected farms. Nevertheless, 
the seroprevalence of PCV-2 antibody in colostrum samples was high (98.5%; 135/137) as 
expected. Interestingly, vaccinated dams had significantly (p=0.0039) higher group mean S/P 
values compared to non-vaccinated dams. 
In this study the overall seroprevalence of PCV-2 antibody in newborn piglets was 
determined to be 43.9%. After initial analysis, the number of seropositive piglets (88.1%; 
297/337) on Farm 1 was not consistent with previous findings on pre-suckle serum sample 
(Shen and others 2010a, Gerber and others 2011). Recent PCV-2 infection of the majority of 
the dams could have resulted in a high horizontal PCV-2 transmission rate after 70 days of 
gestation. However, considering the overall low prevalence rates of PCV-2 viraemic piglets 
(22.8%; 77/338) and of PCV-2 DNA positive colostrum samples (2.9%; 2/69), this seemed 
unlikely. Alternatively, the PCV-2 in-house ELISA could have generated false positive 
results. To rule this out, a subset of seropositive samples were tested with a different 
commercially available competitive ELISA and similar results were obtained. The method of 
blood collection, umbilical cord collection versus jugular vein collection could also have 
affected the outcome possibly due to contamination of the umbilical cord by maternal blood. 
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Finally, colostrum access of the piglets on Farm 1 was confirmed by detecting high total IgG 
OD levels in sera. The piglets were selected by farm workers and lack of colostrum uptake 
was not verified by research workers. It has been determined that colostral-derived antibody 
titres in neonatal pigs can be detected within 2 hours and may peak 9-24 hours after 
colostrum uptake (Lai and others 1986, Vandeputte and others 2001). On Farm 2, piglet 
selection and sample collection was done only by the research team members and therefore it 
was known that colostrum uptake did not occur in Farm 2 pigs. To account for the difference 
in colostrum access between the two farms, the piglet data were analyzed separately for each 
farm. PCV-2 vaccination had a significant (p<0.05) effect on piglet anti-PCV-2 IgG S/P 
ratios in Farm 1 with piglets born to vaccinated dams having higher group mean S/P ratios 
compared to piglets born to non-vaccinated dams. 
Overall, the prevalence of PCV-2-DNA-positive piglets was 11.7%. In post-suckle 
serum samples obtained from Farm 1, there was significantly (p<0.001) lower prevalence of 
viraemic piglets from vaccinated dams (15.4%; 26/169), compared to piglets born to non-
vaccinated dams. The same effect was also seen at the litter level [48.6%, (17/35) litters from 
vaccinated dams versus 82.9% (29/35) from non-vaccinated dams]. Interestingly, the 
detection rates of PCV-2a and PCV-2b were similar (28 samples each; 2/28 PCV2a positive 
samples were identified on Farm 2) which is in contrast to previous results which indicated a 
much higher rate of PCV-2b infection in piglet sera (69.5% versus 15.6%) based on analysis 
of 499 pre-suckle piglet serum samples (Shen and others 2010a). Contrary to previous 
studies, the current study utilized PCV-2 vaccination in a portion of the dams which may 
have interfered with PCV-2 subtype specific viral replication. It is well established that PCV-
2 infection during early to mid- term gestation can cause sporadic reproductive failure (West 



and others 1999, Johnson and others 2002, Sanchez, Jr. and others 2004, Mikami and others 
2005). However, the impact of PCV-2 circulation in a breeding herd may be more important 
in the neonatal and growing pig than it is in the dam.  
Higher incidences of PCVAD are often encountered after maternal antibodies begin 
to wane (Opriessnig and others 2004) when sub-clinically infected piglets are being 
comingled with naïve, growing animals. While the parameters of this study did not allow for 
observation of mortality and morbidity of the pigs throughout the growing period, the 
prevalence of viraemic piglets from vaccinated dams was significantly lower than in pigs 
born to non-vaccinated dams. In the field, this could lead to less and lower dose exposure to 
other pigs in the barn.    
Although PCV-2 vaccination in growing pigs is now widespread and has resulted in 
decreased incidence of PCVAD (Kixmöller and others 2008, Gillespie and others 2009), 
indications are that they have not been entirely effective. There are several reports of PCV-2-
associated severe, acute pneumonia with pulmonary edema in Kansas and Nebraska (Cino-
Ozuna and others 2011). The emergence of a recombinant virus in Canada in late 2009 
(Gagnon and others 2010) has also raised concerns about vaccine safety. While vaccination 
of sows has been shown ineffective in completely preventing intra-uterine infection from 
either PCV-2 spiked semen (Madson and others 2009a) or experimental challenge (Madson 
and others 2009b) in dams housed under experimental conditions, the results of this study 
corroborates previous findings that sow vaccination reduces the number of viraemic piglets 
by possibly hindering intrauterine infection (Shen and others 2010a) or decreasing infection 
via colostrum shortly after birth. 



This study further adds to the knowledge on PCV-2 infection in breeding herds and 
the role of dam vaccination on PCV-2 prevalence in neonates. The overall prevalence of 
PCV-2 DNA in two Iowa breeding herds in 2011 was lower than reported in previous years. 
Under the study conditions, vaccination of the dams with a commercially available 
inactivated vaccine increased (p=0.0039) colostral anti-PCV-2 IgG. In addition, on post-
suckle sera (Farm 1) vaccination reduced (p<0.001) the overall numbers of PCV-2 viraemic 
piglets and decreased (p=0.036) the prevalence of litters with PCV-2 viraemic pigs.   
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Table 1: Number of samples of colostrum and serum obtained from PCV-2-vaccinated and 
non-vaccinated sows and corresponding piglets on two farms in Iowa, USA. Differences in 
sow numbers and litters are due to inability to collect colostrum from all of the dams.  
Sample type Vaccination Farm 1 Farm 2 Total 
Dam colostrum 
Yes 35 35 70 
No 34 33 67 
Piglet serum 
Yes 169 175 344 
No 169 173 342 
 


 
Table 2: Litter characteristics of the selected sows used in this study. Data presented as 
group mean (se). 
Vaccination  Farm Liveborn Stillborn Mummified 
Yes 
1 12.0 (0.5) 0.9 (0.2) 0.3 (0.1) 
2 12.3 (0.5) 0.9 (0.2) 0.5 (0.1) 
No 
1 11.5 (0.6) 0.7 (0.4) 0.1 (0.0) 
2 12.3 (0.4) 1.4 (0.3) 0.3 (0.1) 
 


 
Table 3: Prevalence of anti-PCV-2 antibodies, mean group ELISA sample-to-positive (S/P) 
ratios, and overall prevalence of PCV-2 DNA and prevalence of PCV-2 subtypes (PCV-2a, 
PCV-2b, or both). 
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Table 4: Prevalence of litters with 0, 1-2, or 3-4 or 5 anti-PCV-2 antibody positive pigs and 
prevalence of litters with 0, 1 or 2-3 PCV-2 DNA positive pigs from PCV-2 vaccinated or 
non-vaccinated dams at each of two farms. 
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CHAPTER 5 – GENERAL CONCLUSIONS 
1.  Systematic review and pairwise meta-analysis of the three commercially available 
PCV2 vaccines in the United States   
 Vaccination against PCV2 is commonly used and it is estimated that approximately 
99% of the growing pigs in the United States are vaccinated against this virus (Shen et al., 
2012a). Despite the widespread prevalence of vaccination, there are currently very few 
studies comparing the efficacy of PCV2 vaccines, and recent advances in systematic reviews 
and meta-analyses (Glenny et al., 2005; Sargeant et al., 2006; O'Connor et al., 2010; Dias et 
al., 2011) have made such methods ideal to determine and compare efficacy. The few 
previous PCV2 vaccination meta-analyses focused on overall vaccine efficacy (Kristensen et 
al., 2011), the performance of Ingelvac® CircoFLEX™ when compared to non-vaccinated 
animals (Holck et al., 2010; Coll et al., 2010), or the comparative efficacy of Ingelvac® 
CircoFLEX™ against Circumvent® PCV (Diaz et al., 2010). This is the first pairwise meta-
analysis of all three vaccines commercially available in the United States. 
 Within the context of this meta-analysis, Ingelvac® CircoFLEX™ and Circumvent® 
PCV were demonstrated to significantly increase ADG, regardless of PRRSV status of the 
herd. Additionally, the limited number of studies available for Suvaxyn® PCV2/Fostera™ 
PCV most likely affected the heterogeneity and effectiveness of the random-effects weighted 
model, and there was no significant difference in ADG between vaccinated and non-
vaccinated pigs for this product. 
A major concern when evaluating literature to be included in the systematic review 
portion of a meta-analysis is utilizing conference proceedings, or “gray” literature. 
Conference proceedings can add to the final dataset by avoiding potential inclusion of bias 


 
due to inaccessibility or language barriers (Sargeant et al., 2006). However, limitations of 
size and inconsistent data reporting can severely limit the usefulness of these studies. 
Furthermore, it has recently been demonstrated that conference proceeding abstracts are more 
likely to report positive results than refereed studies (Snedeker et al., 2010) and may 
therefore alter the outcome of the meta-analysis.    
The results of this pairwise meta-analysis demonstrated a relative rate of efficacy for 
Ingelvac® CircoFLEX™ and Circumvent® PCV, but not a comparative efficacy between 
products. While this information can be useful, it is not automatically applicable or intended 
for comprehensive decision making (Dias et al., 2011). The use of a mixed treatment 
comparison meta-analysis (Dias et al., 2011), analyzing not only vaccination versus non-
vaccination, but also different vaccines in a product-to-product comparison while 
maintaining the individuality of each study (Glenny et al., 2005; Dias et al., 2011), would be 
an ideal next step for meta-analysis of PCV2 vaccine efficacy. Additionally, with the 
development of such a model, routine updating every 18-24 months and inclusion of newer 
or previously excluded products would allow for better insight to current trends. Finally, 
mixed treatment comparison meta-analysis with regular maintenance would allow for 
stochastic interpretation of vaccine efficacy, and would be easily applicable to in-depth cost 
analysis.  
2. Studies on PCV2 vaccination of 5-day-old piglets   
Because PCV2 vaccination is widely used, producers and practitioners continually try 
to adjust recommended vaccination protocols to their own farm specific needs, especially 
with regards to timing and dose (Cline et al., 2008; Jacela et al., 2011; Thacker et al., 2012). 


 
While it is recommended to follow manufacturers’ suggestions and vaccinate at three weeks 
of age when pigs are typically weaned, an earlier vaccination age would perhaps minimize 
labor cost and stress; hence, our second study investigated PCV2 vaccination at either 5 or 21 
days of age with two different commercially available products followed by experimental 
challenge to evaluate vaccine performance.  
The pigs utilized for this experiment were PCV2 naïve and therefore seronegative at 
the time of vaccination. Vaccination with the chimeric vaccine resulted in significantly 
higher sample to positive (S/P) ratios compared to vaccination with the product based on the 
PCV2 capsid protein, regardless of vaccination age. Similar findings were also observed with 
the obtained PCR data. One of 16 pigs in the chimeric groups was positive for PCV2 DNA at 
one of three time points (7, 14, and 21 days) after PCV2 challenge. In contrast, in the subunit 
groups, at 14 and 21 days post PCV2 challenge, 43.75% (7/16) and 25% (4/16) of the pigs 
were viremic, respectively. 
While we did observe differences in both antibody response and levels of viremia 
between products, both products were efficacious in the prevention of PCVAD when 
compared to the non-vaccinated, positive control pigs. After necropsy, post-mortem 
evaluation of selected lymphoid tissues demonstrated no significant differences between any 
of the vaccinated groups and the non-challenged negative control group, while there was a 
significant difference between all vaccinated groups and the non-vaccinated challenged 
positive control group, demonstrating a reduction in the development of clinical PCVAD. 
Furthermore, the differences observed between the vaccine product groups were minimal, 
regardless of vaccination age. This demonstrated that not only were the products efficacious, 
pig age at the time of vaccination did not alter the efficacy of the product. 


 
Previously, maternal immunity has played a role in vaccine failure against swine 
influenza virus (Blaskovic et al., 1970; Mensik et al., 1971; Loeffen et al., 2003), though 
passive immunity has not been shown to affect PCV2 vaccine efficacy under experimental 
conditions (Opriessnig et al., 2008). For this study, it was important to use naïve pigs due to 
the difficulties observed with reproduction of PCVAD in seropositive pigs (Opriessnig et al., 
2004; Shen et al., 2012b). Furthermore, the use of naïve pigs allowed us to use fewer animals 
to definitively demonstrate that the neonatal piglet immune system is capable of mounting an 
appropriate immune response to vaccination, and develops efficient humoral immunity to 
later challenge against PCV2.  
Overall, our results indicated that vaccination at 5 days of age was efficacious and 
safe, and decreased PCV2 viremia and PCV2-associated lesions in a triple challenge model 
using PCV2b, PRRSV and PPV. 
In light of recent evidence of possible maternal interference under field conditions 
(Fraile et al., 2012), this early vaccination study would be ideally performed as a clinical trial 
in the field with a larger cohort from a breeding herd in which the piglets possess detectable 
and varying levels of maternal antibodies prior to vaccination.  
3. Vaccination of sows reduces the prevalence of PCV2 viremia in their piglets under 
field conditions   
Dam vaccination against PCV2 is a method producers would like to use to prevent 
both vertical and horizontal PCV2 transmission to offspring and reduce or even prevent 
PCV2 viremia in piglets at an early age and before an active piglet vaccination would work 
(Opriessnig et al., 2009; Madson et al., 2009a; Madson et al., 2009c; Opriessnig et al., 2010; 
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Kurmann et al., 2011; Fraile et al., 2012). To better identify the efficacy of dam vaccination, 
our third study focused on its role in PCV2 prevalence in offspring. Our results demonstrated 
a lower overall PCV2 viremia in piglets derived from vaccinated dams that had colostrum 
access prior to serum collection. 
Due to variances in farm management practices resulting in blood collection of Farm 
1 pigs after suckling and of Farm 2 pigs before suckling, adjustments to the data analysis had 
to be made. Analysis of the data at the farm level allowed for an evaluation of PCV2 viremia 
in post-suckle serum and the role of colostrum uptake on viremia in the offspring. It was 
determined that PCV2 viremia was reduced in offspring of vaccinated dams with colostrum 
access. 
Another interesting observation was the prevalence rates of the two main PCV2 
genotypes. We observed equivalent prevalence of PCV2a and PCV2b in contrast to earlier 
findings of greater prevalence of PCV2b (Shen et al., 2010), indicating a potential ecological 
shift of the virus on the investigated farms which could be attributed to widespread 
vaccination (Shen et al., 2012a). 
Overall, the results of this study demonstrated that piglets with colostrum access 
derived from vaccinated dams had significantly higher amounts of anti-PCV2 antibodies than 
those derived from non-vaccinated dams. Additionally, piglets with colostrum access derived 
from vaccinated dams had a significantly lower prevalence of PCV2 viremia as opposed to 
those derived from non-vaccinated dams. Furthermore, there was a significantly higher rate 
of litters containing one to three PCV2 viremic piglets when they were farrowed from a non-
vaccinated sow.  

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A more geographically diverse field study utilizing dam vaccination that focuses on 
solely pre- or post-suckle serum collection would allow for better characterization of the 
potential vaccination influence on the shift in PCV2 prevalence. Additionally, evaluation of 
different PCV2 vaccines as well as vaccination times relative to estrus and gestation in dams 
is vital to optimize breeding herd vaccination. Finally, comparing the offspring from 
vaccinated and non-vaccinated dams from farrow to finish would be ideal to determine if 
dam vaccination contributes to performance.     
4. Final conclusion 
In conclusion, PCV2 vaccination continues to be the first line of defense against the 
development of the economically important disease manifestations comprising PCVAD. We 
demonstrated that vaccination in either growing age pigs or dams is safe and efficacious, and 
that the use of PCV2 vaccines increases production parameters. Overall, this thesis 
contributes to the collective knowledge about PCV2 vaccination and novel methods in their 
administration. 
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